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Nausea and emesis can be induced by a wide variety of challenges and often 
represents a limit of drug therapy. The forebrain is involved in emesis control but 
little is known about its connectivity to reflex brainstem centres. The primary aim of 
the project was to identify forebrain and hindbrain areas involved in the emesis 
induced by cisplatin using the ferret and <z-fos immunohistochemistry. The studies 
were complemented by detailed behavioural investigations of cisplatin and other 
emetic drugs in the ferret and Suncus murinus. 
Cisplatin (10 mg/kg, i.p.) induced emesis in the ferret (P<0.001) without modifying 
spontaneous locomotor activity (P>0.05); the emesis was antagonized significantly 
(P<0.001) by CP-99,994 (a NKi receptor antagonist; 10 mg/kg, i.p.) and ondansetron 
(a 5-HT3 receptor antagonist; 1 mg/kg, i.p.). In these experiments, CP-99,994 (alone 
and in combination with cisplatin) significantly increased spontaneous locomotor 
activity (P<0.05) of ferrets and decreased spontaneous lip licking (P<0.05); 
ondansetron appeared to have a subtle action to decrease the incidence of defecation 
(P<0.05). No o-fos positive cells were detected in the hindbrains of the ferrets 
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(because of technical difficulties and forebrains were not subsequently processed). 
Apomorphine (0.25 mg/kg, s.c.) also induced emesis (P<0.01) and increased 
spontaneous locomotor activity (P<0.05); the emesis was antagonized by 
domperidone (a dopamine receptor antagonist; 1 mg/kg, i.p.) and CP-99,994 (10 
mg/kg, i.p.) (PO.OOl); CP-99,994 also had a subtle action to reduce lip licking 
behaviour when combined with apomorphine (P<0.01). In Suncus muriniis, nicotine 
(5 mg/kg, S.C.), copper sulphate (120 mg/kg, intragastric) and cisplatin (30 mg/kg, 
i.p.) induced emesis that was antagonized by CP-99,994 (P<0.05; 3-10 mg/kg, i.p. 
and S.C.); nicotine and cisplatin in some experiments reduced locomotor activity but 
the reductions were not prevented by CP-99,994. Ondansetron (1-3 mg/kg, s.c.) also 
reduced cisplatin-induced emesis (PO.OOl) but had no effect on locomotor activity 
r 
measures (P>0.05). 丨 
In conclusion, emetic drugs may have complex and disparate actions on ferret and 
Suncus murinus behaviours that appear to be species dependent. CP-99,994, 
ondansetron and domperidone predictably antagonized emesis and CP-99,994 had a 
novel profile to modify some spontaneous behaviours in the ferret. The studies 
provide a valuable framework for a study of nausea and emesis in animals that may 
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CHAPTER 1 INTRODUCTION 
1.1 General Introduction 
There are several major classes of drugs available for the treatment of nausea and 
emesis. These include antagonists acting at dopamine, histamine, muscarinic and 5-
hydroxytryptamines (5-HT3) receptors. These agents probably reduce nausea and 
emesis by blocking receptors on afferent inputs into the so-called vomiting centre 
(see below) and this limits their spectrum of activity. However, the tachykinin NK! 
receptor antagonists represent a new range of anti-emetic drug that probably prevent 
emesis at sites deeper in the vomiting reflex and therefore have a remarkable 
spectrum of action in animals to prevent vomiting induced by a wide variety of 
challenges (Bountra et al, 1993; Gardner et al., 1996; Gardner et al., 1995). This 
broad inhibitory anti-emetic action, in the absence of dangerous side effects, has 
resulted in the NKi receptor antagonists being evaluated in the c l in i c� In particular, 
the NKi receptor antagonists have been evaluated for their potential to reduce 
chemotherapy-induced acute and delayed nausea and emesis (Campos et al., 2001; 
Hesketh et al” 1999; Navari et al., 1999) and also the nausea and emesis following 
surgery with anaesthesia (Diemunsch et al., 1999; Gesztesi et al., 2000). 
At the start of the present studies, there was a concern that the NKi receptors 
antagonists were acting at sites distal to the afferent inputs to the vomiting centre and 
that whilst emesis could be blocked, it may still be possible that ongoing afferent 
activity could still trigger the- sensation of nausea via mechanisms prior to the 
location of the NKi receptor. Unfortunately, it was not possible to determine the 
action of the NKi receptor antagonists on nausea in animals since they are unable to 
communicate directly their emotional status. Subsequently, L-758,298 (the pro-drug 
1 
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for the NKi receptor antagonist L-754,030) has been found to be ineffective to 
reduce motion-induced nausea in man (Reid et aL, 1998). Another NKi receptor 
antagonist, GR 205171, also lacked efficacy against motion-induced nausea (Reid et 
a l . 2000). However, the activity of the NKi receptor antagonists against 
chemotherapy-induced nausea and emesis has been partially established (Cocquyt et 
aL, 2001; Navari et aL, 1999), but most studies have been conduced in combination 
with other anti-emetic drugs, making an absolute assessment of the action of the 
blockers on nausea difficult. 
This thesis describes a set of experiments designed to investigate the anti-emetic 
potential of NKi receptor antagonists to inhibit emesis and associated behavioural 
changes in the Suncus murinus and ferret. Some of these behavioural measures have � 
been previously considered to be markers of nausea in animals. However, the project • 
also attempted to use the technique of Q-fos immunohistochemistry to identify a 
possible activation of forebrain areas in the ferret by emetic treatments and 
investigated if the NKi receptor antagonist, CP-99,994, could prevent any potential 
increase in activity. This would provide new information about the basic 
connectivity of the vomiting reflex and the role of the NK] receptor and may answer 
the question about the site at which the NKi receptor antagonists act to prevent 
emesis and if they can also prevent the potential transfer of signals from the 
brainstem to the forebrain. The studies may provide a new model to predict if a 
compound has the potential to prevent both nausea and emesis, before it progresses 
to expensive studies in man. A brief introduction of the mechanisms involved in 
emesis control and the available animal models of nausea are detailed below� 
Background information on the c-fos immunohistochemical technique is also 
provided. 
2 
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1.2 Emesis 
1.2.1 Introduction 
Emesis is believed to be a protective mechanism that has evolved to protect against 
the accidental ingestion of toxins. Its significance maybe similar to the action of 
coughing as a mechanism to protect the airways (Andrews & Sanger, 1993a). It has 
been suggested that emesis can be regarded as a second level of defense against 
potential toxins, whilst taste, smell and sight are regarded as the first defense level 
(Davis et al., 1983). 
Emesis can also be elicited by a number of other causes. For example, it has been 
documented that provocative motion (Money, 1970), pregnancy (Fairweather, 1968), 
anaesthetics used in surgery (Clarke, 1984) and diseases, for example Meniere's 
disease (Longridge, 1983) can evoke emesis in individuals (Mitchelson, 1992). 
Importantly, emesis is also a distressing side effect of cancer chemotherapy or 
radiotherapy that may actually discourage patients from receiving further life-saving 
treatment (Allan, 1987). 
1.2.2 Retching & Vomiting 
Vomiting is the forceful expulsion of upper gastrointestinal contents via the mouth� 
It usually, but not always, preceded by retching, in which no expulsion of material 
takes place (Andrews, 1992). The somatic muscles of the diaphragm, intercostals 
and abdomen contract in a coordinated manner during both retching and vomiting 
and muscle strain and fatigue may occur in some extreme cases. Although vomiting 
is distressful, the significance of retching should not be underestimated since the 
3 
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frequency of retching is usually greater than that of vomiting (Andrews & Sanger, 
1993a). : 
L2.3 Nausea 
Nausea can be defined as an unpleasant, but not painful, sensation associated with a 
heightened awareness of the upper gut (throat，oesophagus and/or stomach) and the 
conviction that vomiting is imminent (Andrews & Davis, 1993b). It is regarded as 
one of the most distressing side effects of anti-cancer treatment (Coates et al., 1983). 
The manifestation of nausea is accompanied by a loss of gastric tone, a decrease in 
peristaltic activity, a contraction of duodenum and a reflux of intestinal contents into 
the stomach (Tonato et al., 1993). In view of the fact that vomiting may be regarded 
as a physiological means of eliminating toxins from the body, the establishment of 
nausea may aim at stopping further ingestion of the toxin, via the development of a 
learned aversion so that the toxin can be rejected before ingestion if it is encountered 
again (Andrews, 1992). Nausea is often also accompanied by a number of 
physiological events. They include cold sweating, skeletal muscle vasodilatation, 
licking, salivation, cutaneous vasoconstriction and headache (Andrews & Davis, 
1993b). 
In contrast to retching and vomiting, nausea is a subjective sensation that renders 
accurate assessment and recording difficult. Whilst self-reporting from patients is 
feasible, the study of nausea in animals is problematic. Several putative measures of 
nausea in animals have been suggested and they will be discussed in greater detail in 
later part of this thesis. 
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1.2,4 Motor Components of Emetic Reflex 
1.2.4.1 Pre-ejection Phase 
The pre-ejection phase, which is also known as the prodromal phase, is often 
accompanied with the sensation of nausea. It first starts with a relaxation of the 
proximal stomach, which may aim at preventing the ingested toxins from moving 
further down the gastrointestinal tract. At the same time, gastric acid secretion is 
also inhibited. Intestinal contraction, originating from the mid-intestine, propagates 
in a retrograde manner towards the stomach. This retrograde giant contraction 
(RGC), which is mediated via acetylcholine, returns contaminated intestinal contents 
to the stomach ready for ejection. In addition, alkaline intestinal secretions may also 
r 
help in neutralizing the acidic gastric content from damaging the teeth and 
oesophagus. Upon the RGC reaching the stomach, retching and vomiting may 
occur imminently (Andrews & Davis, 1993b). 
1.2.4.2 Ejection Phase 
This phase consists of both retching and vomiting. During retching, the diaphragm, 
the rectus abdominis and the external intercostal muscles undergo contraction. The 
sole effect of these contractions is an establishment of a rhythmic decrease in intra-
thoracic pressure with concomitant increase in intra-abdominal pressure. 
Vomiting normally commences shortly after retching. During vomiting, the 
perioesophageal diaphragm is relaxed, in which the passage of gastric content into 
the oesophagus is facilitated. Concomitantly, the rectus ah do minis muscles contracts 
in a more powerful and prolonged manner than that occurs during retching. The net 
5 
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effect of these events is that a strong expulsive force is generated in which the 
stomach is compressed. Normally, this compression is enhanced by a characteristic 
posture adopted by the vomiting individual, which also helps in minimizing the stress 
on the muscle groups and structures that are not involved in vomiting (Andrews & 
Davis, 1993b). 
1.2.4.3 Post-ejection Phase 
Following vomiting, subjects usually report “feeling better" and the sensation of 
nausea is normally alleviated. The exact physiology of this is still unknown but an 
involvement of endorphins is suspected (Andrews & Davis, 1993b). 
L 2.5 Components of Emetic Reflex 
1.2,5.1 Area Postrema (AP) 
The area postrema (AP) is a U-shaped bilateral structure a few millimeters long 
located in the caudal part of the fourth ventricle in the region of the obex (Andrews, 
1992). There is a lack of a proper blood-brain barrier in the AP as there are no 
effective intercellular occluding junctions between the ependymal cells that cover the 
region (Leslie & Reynolds, 1993). This lack of a tight blood-brain barrier facilitates 
the detection of toxins in the blood and cerebrospinal fluid. It is well accepted that 
the chemoreceptor trigger zone, which is active in detecting a great number of emetic 
stimuli, is located within the AP (Andrews & Davis, 1993b). The AP has a close 
reciprocal connection with the nucleus tractus solitarius (NTS) (which is another 
6 
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important component in the emetic reflex to be discussed in greater detail in the 
section below) (Leslie & Reynolds, 1993; Miller et al,, 1994). It is noteworthy that 
the AP may have other functions, apart from those in the emetic reflex, as it can be 
found in both emetic (e.g. ferret) and non-emetic species (e.g. rat) (Andrews, 1992). 
Many neurotransmitters and their respective receptors have been identified in the AP 
(see Table 1.1). Apart from the roles of these receptors in detecting aversive agents, 
the existence of some neurotransmitters and receptors may also be involved in 
autonomic nervous responses in mediating the emetic act (Leslie & Reynolds, 1993). 
Table 1.1 Neurotransmitters found in medium-to-high concentrations in the area 
postrema (Modified from (Leslie & Reynolds, 1993)). 
Area postrema  
Alpha-neo-endorphin Leu-enkephalin ‘ 
Beta-neo-endorphin Luteinizing hormone-releasing hormone 
Dopamine Met-enkephalin 
Dynorphin A Neurotensin 
Dynorphin B Noradrenaline -
Gamma-aminobutyric acid Serotonin 
Glutamate Vasoactive intestinal peptide 
Glycine  
1.2.5.2 Nucleus Tract us Solitarius (NTS) 
The nucleus tractus solitarius (NTS) is another important brain area involved in the 
emetic reflex. The NTS receives afferent information from the vagus (Leslie & 
Reynolds, 1993). There are also many afferent and efferent connections between the 
AP and the NTS (Carpenter, 1990). In contrast to the AP, NTS is equipped with a 
proper blood-brain barrier. Nevertheless, a subdivision of the NTS, namely 
subnucleus gelatinosus (SNG), is similar to the AP. It may be reasonable to 
speculate that AP is simply an extension of this part of the NTS into the fourth 
7 
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ventricular lumen. The extensive localization of gastric vagal afferent terminals in 
the SNG enforces its significance in the emetic reflex (Leslie & Reynolds, 1993). 
In late 1940s，Borison and Wang suggested that the NTS might be the place where 
the ‘‘vomiting centre" (a discrete centre in the brain responsible for coordinating the 
emetic act) was located (Borison & Wang, 1949). Whilst the existence of such 
discrete ‘‘vomiting centre" is still hotly debated, the NTS may indeed be involved as 
a "central pattern generator", which is active in coordinating the sequential firing of 
emetic motor units in an orderly manner (Carpenter, 1990; Davis et al., 1983; Leslie 
& Reynolds，1993). In fact, the importance of the NTS within the emetic reflex is 
realized by the extensive numbers of neurotransmitters and their respective receptors 
found 才ithin the region (see Table 1.2). 
Table 1.2 Neurotransmitters found in medium-to-high concentrations in the nucleus 
tractus solitarius (Modified from (Leslie & Reynolds，1993)). 





Angiotensin II Leu-enkephalin 
Aspartate Melatonin 
Atrial natriuretic peptide Met-enkephalin 
Beta-neo-endorphin Neurotensin 
Bombesin Noradenaline 
Cholecystokinin Neuropeptide Y 
Corticotropin-releasing factor Oxytocin 
Dopamine Serotonin (5-HT) 
Dynorphin A Somatostatin 
Dynorphin B Substance P 
Endothelin Taurine 
Gamma-aminobutyric acid" Thyrotropin-releasing hormone 
Gamma-melanocyte-stimulating hormone Vasopressin 
Glucagons Vasoactive intestinal peptide  
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1.2,5.3 Vomiting Centre 
The concept of a discrete and localized "vomiting centre" in centralizing the 
vomiting reflex was suggested by Borison and Wang in the late 1940s (Borison & 
Wang, 1949). Electrical stimulation studies in unanaesthetized, decerebrated cats 
demonstrated that such a "vomiting centre" might also be located in deeper 
brainstem areas. More precisely, the solitary tract and the reticular formation might 
be involved in coordinating the emetic reflex. Such speculation was confirmed by 
experimental results showing that lesion of these brain areas impairs the vomiting 
response of dogs (Wang & Borison, 1951). However, Miller and Wilson (1983) 
failed to obtain reproducible vomiting by electrically stimulating these brainstem 
areas in cats. Apart from the difference in incidences and onsets of vomiting 
between the studies, discrepancies also exist in the incidence of prodromal signs of 
emesis, such as salivation and mouth opening. The existence of a discrete and 
localized "vomiting centre，，was thus in question. Instead, it was suggested that 
vomiting might actually be coordinated by a distributed control system, which 
involved both autonomic and somatic nerve interventions (Miller et al, 1983). 
Notwithstanding these newer ideas, it is believed that the reticular formation might 
play a vital role within this coordinated system (Miller et al., 1994). 
More recent studies have been conducted by Fukuda and Koga in 1991. Other than 
the highlighted role of the reticular formation, the importance of the Botzinger 
complex as a pattern generator in the vomiting reflex was also reviewed. It was 
suggested that the emetic signal from the stomach might actually passed through the 
solitary complex and the area subpostrema and may converge with projections from 
9 
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the area postrema，to the Botzinger complex, followed by the reticular formation 
(Fukuda er a/., 1991). 
1.2.5,4 Vestibular System 
It has been shown that the vestibular labyrinthine system is essential for the 
development of motion sickness, which may actually due to sensory conflict within 
the body (Mitchelson, 1992; Oman, 1990; Reason, 1978). There are experiments 
showing that the position of the head (and hence the degree of labyrinthine 
stimulation) can modulate apomorphine-induced emesis in man (Isaacs, 1957). 
Further, it has been shown that the emetic responses to lobeline, L-dopa and nicotine, 
� 
but not of pilocarpine or apomorphine, are reduced by the removal of vestibular 
system (Money et al., 1983). 
L 2.5.5 A bdominal Visceral Afferents 
As vomiting may be regarded as the second line of defense against toxin ingestion 
(Davis et al., 1983), it is not surprising that the abdominal visceral afferents actually 
play a major role in the emetic reflex. The vagus, is a member of the twelve pairs of 
cranial nerves and is generally involved in detecting stimuli in the viscera. The 
vagus has 2 systems that can be utilized to activate the vomiting reflex: (1) 
mechanoreceptors and (2) chemoreceptors. The mechanoreceptors are located in the 
muscular wall of the gut and are susceptible to activation by both contraction and 
distension of the gut. They may also be active in signaling abnormal gastro- _ 
intestinal motility patterns that occur in the prodromal phase of emesis (Andrews & 
10 
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Davis, 1993b; Grundy & Scratcherd, 1989). The chemoreceptors, which are located 
in the mucosa of the upper gut, respond to mucosal stroking, acid, alkali, hypertonic 
solutions, temperature and gastric irritants (e.g. copper sulphate) (Andrews & Davis, 
1993b; Grundy et al,, 1991). It should be noted that most of these afferent fibres 
terminate in the NTS. 
There are two major types of motor nuclei of the vagus. These include the dorsal 
motor nucleus of the vagus (DMVN), which contains many of the parasympathetic 
neurons of the vagus that mainly innervates gastrointestinal and respiratory visceral 
structures and the nucleus ambiguous that mainly innervates laryngeal and cardiac 
structures (Andrews & Davis, 1993b). 
Among the different causes of emesis, the abdominal visceral afferents are 
particularly important in the radiation- and cytotoxic drug-induced emesis. Andrews 
et al (1988) suggested that 5-hydroxytryptamine (5-HT) is released from the 
enterochromaffm cells of the gut following radiation and cytotoxic drugs challenges� 
The released 5-HT then activates the vagal afferents which results in emesis 
(Andrews et al” 1988a). 
1.2.5.6 Forebrain 
To date, most of the information relative to the emetic reflex is centred on the 
brainstem. In contrast, the possible involvement of forebrain is much less 
documented. Preliminary evidence suggesting the forebrain’s involvement in the 
emetic reflex emerged from emesis induced by electrical stimulation studies of 
forebrain in the monkey (Robinson et al., 1968). Thus, it has demonstrated that 
11 
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electrical stimulation of certain forebrain areas, such as the amygdala and 
hypothalamus, effectively produced vomiting. It has also been shown that midbrain 
section impairs drug (i.e. cisplatin and apomorphine)-induced emesis in ferrets 
(Naylor & Rudd, 1990). Apart from the aforementioned studies, recent 
investigations about conditioned taste aversion (which has been regarded as putative 
measure of vomiting and nausea) provided further clues to suggest the possible 
involvement of forebrain in the emetic reflex. By using Q-fos immunohistochemistry, 
it has been demonstrated that amygdala (Gu et al., 1993; Schafe et aL, 1996), 
hypothalamus (Gu et al., 1993) and insular cortex (Schafe et aL, 1998), have 
elevated activity after the treatment with emetic stimuli. The possible involvement 
of the hypothalamus in the emetic reflex has also been confirmed by studies using 
cats (Beleslin et cd., 1987b). Last but not least, it should always be remembered fhat 
the occurrence of anticipatory nausea and vomiting after chemotherapy in the clinic 
(in which the limbic system and higher cerebral intervention are believed to be _ 
involved) also provides us with the evidence that the forebrain may be involved in 
the emetic reflex (Aapro et al., 1994; Harris, 1985). 
1.2.6 Neurotransmitters & Receptors 
To date, a number of studies have been carried out in order to highlight the different 
types of neurotransmitters and their respective receptors involved in the emetic 
reflex. Briefly, adrenergic, cholinergic, dopaminergic, histaminergic, serotonergic, 
opioid and tachykinin systems are involved. Each neurotransmitter system may 
subserve a particular importance in mediating a specific type of emesis. For 
instance, muscarinic (Pedigo et al., 1985) and histaminergic (Bhargava et al., 1976) 
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transmitter systems are greatly involved in motion-induced vomiting. Conversely, 
serotonin is more extensively involved in the radiation- and cytotoxic drug-induced 
emesis (Andrews et al, 1988a). A summary of neurotransmitters and their 
respective receptors in the emetic reflex is shown below. 
Table 1.3 Neurotransmitters and receptors involved in the emetic reflex. 
Receptors Neurotransmitters Studied in species References 
Adrenergic Noradrenaline and Dog Hikasa et al. 1992 
adrenaline Cat Beleslin e /a / . , 1987c 
Cholinergic Acetylcholine Cat Beleslin et al., 1988 
(Muscarinic & Nicotinic) Beleslin et al., 1987a 
Dog Lefebvre et al., 1981 
Cow Pedigo et al., 1985 
Dopaminergic Dopamine Man Isaacs, 1956 
Dog Niemegeers, 1971 
Ferret Yoshikawa etal, 1996 
I Least shrew Darmani et al, 1999 
Histaminergic Histamine Dog Bhargava et al., 1968 
Bhargava et al., 1976 
Opioid Morphine & enkephalins Dog Bhargava et al., 1981 
Ferret Barnes et al., 1991 
Suncus murinus Rudd et al., 1999a 
Serotonergic Serotonin Man Priestman et al., 1990 
(5-HTIA, 5-HT2,5-HT3) Cat Lucot et al., 1987 
Pigeon • Wolff a/., 1995 
Ferret Rudd etal., 1994 
Suncus murinus Javid et al., 2002 
Tachykinin Substance P Dog Watson et ai, 1995 
(NKi) Ferret Rudd et al., 1996b 
Suncus murinus Rudd et al., 1999b 
Vanalloid Unknown Ferret Andrews et ai, 1993 
Suncus murinus Andrews et al., 2000 
1.2,7 Anti-emetics 
By virtue of the fact that prolonged nausea and vomiting can lead to nutritional 
deficiency, electrolyte imbalance, dehydration, fatigue, disruption of lifestyle or even 
discouragement to cancer patients from receiving further treatment, alleviation of 
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symptoms by effective anti-emetics is of vital importance (Rhodes et al., 1997). To 
date, a number of classes of anti-emetics have been developed. As nausea and 
vomiting can be induced via different pathways in the body, it was once thought that 
no universal anti-emetic could be developed (Leslie et al” 1990). The clinical uses 
of different classes of anti-emetics and their side effects induced are summarized in 
Table 1.4. 
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Table 1.4 Clinical uses of different classes of anti-emetics and their respective side 
effects. 
Types of anti- Examples Conditions used Side effects  
emetics  
Benzodiazepine Lorazepam ANV Sedation (Harris, 1985； 
Leslie et al., 1990) ‘ 
Cannabinoid Nabilone CIE (more effective •:• Sedation (Leslie e/ al.. 
Tetrahydrocannabinol in children oncology) 1990) 
Dizziness (Leslie et al., 
1990) 




•:• Somnolence (Harris, 
1985) 
Dopamine D2 Chlorpromazine CIE Side effects similar to 
receptor antagonist Domperidone RIE Parkinson's disease 
Metoclopramide PONV (Leslies/ ai, 1990) 
Migraine <• Cardiac arrhythmia 
::� (Harris, 1985) 
Convulsion (Harris, 
. 1985) 
<* Drowsiness (Harris, 
1985) 
Histamine receptor Dimenhydrinate Motion sickness *> Sedation (Leslie, 1993) 
antagonist Diphenhydramine Morning sickness 
PONV 
5-HT3 receptor Ondansetron CIE *> Mild constipation and 
antagonist Granisetron RIE headache (Jones & 
Tropisetron Cunningham, 1993) 
Muscarinic receptor Scopolamine (hyoscine) Motion sickness <• Dry mouth (Mitchelson, 
antagonist Atropine Morning sickness 1992) 




•:• Impaired leaning and 
memory (Leslie et al., 
1990) 
Steroid Dexamethasone CIE *> Inadvisability for long-
term use (Sakata et al., -
1986) 
Remarks: 
(1) ANV: Anticipatory nausea and vomiting _ 
(2) CIE: Chemotherapy-induced emesis 
(3) RIE: Radiation-induced emesis 
(4) PONV: Post-operative nausea and vomiting 
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It is worth-noting that most of the aforementioned anti-emetics do possess a different 
extent of side effects that limit their clinical uses. Further development of new anti-
emetics is therefore required. Although the exact identity of the "vomiting centre" is 
still in question, further investigation in this area will surely be beneficial to future 
anti-emetic development. 
In fact, among the aforementioned anti-emetics that have clinical significances, the 
tachykinin NKi receptor antagonists are currently under clinical investigation. It has 
been shown that certain NKi receptor antagonists (e.g. CP-122,721 and CJ-11,974) 
are active in alleviating chemotherapy-induced vomiting, especially during the 
delayed phase. More intriguingly, the ability of the NK! receptor antagonists in 
reducing nausea in chemotherapy-receiving patients has also been highlighted 
(Hesketh et al., 1999; Kris et al., 1997). Apart from the chemotherapy as a cause of 
emesis, it seems that the NKi receptor antagonists are also active in alleviating the 
post-operative nausea and vomiting (PONV) (Gesztesi et al., 2000). Moreover, it is 
noted that the efficacies of the NKi receptor antagonists are augmented by the co-
administration with current anti-emetic regimes, such as the 5-HT3 receptor blockers 
(e.g. ondansetron) or glucocorticoids (e.g. dexamethasone). 
1.3 Models of Nausea 
1.3.1 Introduction 
Nausea is an unpleasant and subjective sensation of discomfort referred to the upper 
gut that is often associated with the awareness of the urge to vomit (Tonato et al., 
1993). However, nausea does not necessarily culminate in vomiting. Nausea is 
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often described as the feeling "sick" in the stomach (Rhodes et al., 1997). To date, 
the etiology of nausea still remains u n k n o w n � T h e development of a valid animal 
model will be definitely beneficial to the study of the neural and physiological 
systems involved. Humans can report their severity of nausea in terms of frequency, 
intensity and duration. This is done using visual analogue scales or descriptive 
ordinal scales (Tonato et al., 1993) but such measurements are not feasible in 
animals. Instead, a number of other methods have been suggested to provide an 
index of nausea in animals (Table 1.5). In the following sections, some of these 
putative measures will be discussed in greater detail. 
Table 1.5 List of putative measures of nausea that have been used in different 
animal species. (Modified from (Fox, 1992)) ：-
Putative measures Animal species References  
Conditioned taste aversion Human, Bernstein et ai, 1980 
Cat Rabin et al., 1986 
Squirrel monkey Roy et al., 1979 
Rat Schafee / t? / , 1996 
Ferret Rabin et al., 1992 
Suncus murinus Smith et al, 2001 
Pica behaviour Rat Takeda a/., 1995 
Mice Yamamoto et al., 2002a 
Vasopressin release Human Rowe et ai, 1979 
Monkey Verbalis et al., 1987 
Rat Verbalis et al., 1986 
Tachygastria Human Stem et al, 1985 
Cardiac rhythm Human Morrow, 1990 
Squirrel monkey Ishii et al., 1987 
Defecation Rat Ossenkopp & Frisken, 1982 
Reduced water intake Rat Haroutunian et al., 1976 
Reduced food intake Human Feyer et al., 1998 
Rat Winsauer et al., 1994 
Reduced activity Rat Eskin & Riccio, 1966 
Skin colour changes Human Morrow, 1990 
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1' 3.2 Conditioned Taste A version 
Conditioned taste aversion (CTA) is defined as the avoidance of flavoured 
substances consumed just before the onset of sickness (Fox, 1992). This technique 
was first introduced by Garcia and Ervin in 1968 (Garcia & Ervin, 1968). As CTA is 
observed in humans undergoing nauseogenic chemotherapeutic (Bernstein, 1985; 
Bernstein et al., 1980)，or radiation treatments (Smith et al., 1984), the suitability of 
CTA as an index of nausea is of interest. 
Conditioned taste aversion has been studied in a number of animal species (Table 
1.5). The general CTA paradigm involves the pairing of a novel gustatory cue (the 
conditioned stimulus) with the administration of a toxic or emetic substance (the 
unconditioned stimulus) (Rudd et al.’ 1998). CTA occurs following various emetic 
stimuli in cats (Fox et al, 1990; Rabin et al； 1986), squirrel monkeys (Fox et al., 
19—90; Roy et al, 1979), ferrets (Rabin et al., 1992), rats (Schafe et al, 1998; Schafe 
et al, 1996) and Suncus murinus (Smith et al., 2001). These experimental results 
further support the use of CTA as an index of nausea. 
In order to study the correlation between CTA and nausea, it is of vital importance to -
investigate whether they share the common neural mechanism. With knowledge that 
the area postrema is an important brain area in the emetic reflex, Fox et al. (1990) 
studied the CTA response in normal area postrema ablated cats and squirrel monkeys 
(Fox et al,, 1990). Interestingly, drug (xylazine and lithium chloride)-induced CTAs 
were inhibited by area postrema ablation, but the lesion had no effect on motion-
induced CTAs. This coincides with the idea that the area postrema is active in 
detecting the blood-borne toxins that may induce emesis. Apart from this study, the 
significant role of the area postrema in drug-induced CTA was also highlighted in 
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some other studies by using different stimuli (such as lithium and copper sulphate) 
(Coil et aL, 1981; McGlone et al., 1980). In addition to the lesion studies, the neural 
mechanism of CTA has also been studied by c-fos immunohistochemistry. Dense 
Fos positive staining was demonstrated in a number of brainstem regions, including 
the nucleus tractus solitarius following lithium chloride (a compound that induces 
gastrointestinal malaise, but not vomiting)-induced CTA (Swank et al, 1994; Swank 
et al； 1995) in rats. With the knowledge that the nucleus tractus solitarius, other 
than the area postrema, is another brain area remains important in the emetic reflex, 
the correlation of CTA with nausea was expected. 
In spite of the fact that a positive correlation between CTA and nausea is established 
by the aforementioned studies, there is also experimental evidence that CTA may not 
be a good model of nausea. For example, there is an inconsistency in the neural 
mechanisms mediating the vomiting reflex and CTA with morphine. Thus, 
morphine-induced vomiting involves the area postrema (Borison et al,, 1962), but 
CTA involves the periaquaductal gray (Blair et al,, 1981). Furthermore, whilst one 
may expect that anti-emetics may be effective in attenuating the CTA induced by 
emetic stimuli, ondansetron (a 5-HT3 receptor antagonist which has clinical 
significance in inhibiting acute chemotherapeutic drug-induced vomiting) is 
ineffective in reducing the cisplatin-induced CTA in rats (Rudd et al., 1998). These 
observations question the suitability of using CTA as a model of nausea. 
Apart from the contradictory findings highlighted above, it is also noteworthy that 
there is inadequacy in using CTA as an index of nausea by virtue of the fact that real-
time and continuous assessment is not allowed (Fox, 1992). Besides, caution must 
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often be paid when studying CTA while psuedoconditioning should always be 
eliminated (Fox, 1992). 
1.3.3 Pica Behaviour 
Pica behaviour is defined as the consumption of a nonfood material such as kaolin 
(Yamamoto et al., 2002a). The precise etiology of pica behaviour still remains 
unknown. However, it has been hypothesized that this specific behaviour helps to 
supply the animals with deficient essential substances (e.g. zinc, calcium, and iron) 
(Yamamoto et al., 2002a). Moreover, Mitchell et al (1977) suggested that animals 
might engage pica for relieving gastrointestinal malaise as it has been reported that 
ancient Greek and Arabs consume clays to relieve nausea and vomiting (Mitchell et 
al., 1977). 
To date, a variety of studies have been carried out to investigate the relationship 
between pica behaviour and nausea and vomiting. In fact, most experiments about 
pica are studied using the rat, a species that does not vomit. Emetic stimuli such as 
apomorphine (Takeda et al., 1995; Takeda et al., 1993), copper sulphate (Takeda et 
al., 1993) and cisplatin (Rudd et al., 2002; Takeda er al., 1995; Takeda et al； 1993; 
Yamamoto et al,, 2002a) induce pica in rats. Collectively, these experimental 
findings provide evidence that pica behaviour may be regarded as an index of 
vomiting and nausea. Apart from the drug-induced pica, it has been shown that 
motion (Mitchell et al,, 1977; Takeda et al, 1995) and radiation (Yamamoto et al., 
2002b) also similarly induce pica. Attempts have also been made to study whether 
the motion-, radiation- and pharmacologically-induced pica— behaviours can be 
inhibited by respective anti-emetic drugs. Interestingly, whilst apomorphine- (a 
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dopamine D2 receptor agonist) and motion-induced pica behaviours are attenuated by 
domperidone (a dopamine D2 receptor antagonist) and diphenhydramine (a histamine 
Hi receptor antagonist) respectively, cisplatin (a chemotherapeutic drug with a 
mechanism of emetic action involving central and peripheral 5-HT3 receptors)- and 
radiation-induced pica is inhibited by ondansetron (a 5-HT3 receptor antagonist). All 
these findings suggested that the mechanisms involved in pica behaviour and the 
emetic reflex are similar. 
Although pica has been demonstrated by several stimuli that commonly cause 
gastrointestinal distress or emesis in human, emphasis is often put into its efficacy to 
act as a model of emesis. Therefore, it is still difficult to comment whether the pica 
behaviour and nausea can be correlated alone. 
1.3.4 Studies of the Involvement of Vasopressin 
Vasopressin is a posterior pituitary peptide hormone that has its main function in the 
kidney. It regulates the body's plasma osmolarity by its anti-diuretic function 
through the V2 receptor located on the basolateral membranes of renal collecting duct 
(Nussey et al,, 1988). In addition, vasopressin also causes vasoconstriction via Vi 
receptor (Rang et al., 1999b). 
Vasopressin has been suggested to be a humoral marker of nausea because an 
elevated level of vasopressin is reported after the administration of various 
nauseagenous stimuli in man. Fisher et al. (1982) demonstrated that elevated level of 
- p l a s m a vasopressin occurred only in the patients who reported nausea and emesis 
after the cancer chemotherapy, but not in those subjects who were symptoms-free 
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(Fisher et al., 1982). Apart from the study during cancer chemotherapy, the level of 
vasopressin has also been studied in man following other emetic stimuli. 
Elevated levels of plasma vasopressin have been demonstrated in response to the 
administration of apomorphine in man (Feldman et al., 1988; Nussey et al, 1988; 
Rowe et al, 1979). More interestingly, the onset of this plasma vasopressin 
elevation coincided with the onset of nausea as reported by the experimental subjects 
(Feldman et al., 1988). In addition, dose-dependent increases in plasma vasopressin 
have been reported following administration of cholecystokinin (CCK) in humans 
(Miaskiewicz et al., 1989). A similar response has also been observed in monkeys, a 
species where elevated levels of vasopressin are also reported to occur following the 
administration of lithium chloride and copper sulphate (Verbalis ef al., 1987). In 
addition, it has also been shown that vasopressin levels are also elevated by motion 
in humans and that vasopressin levels are correlated with the severity of nausea (Xu 
etal, 1993). 
Other than the in vivo experiments mentioned just above, there is some other 
evidence to support a correlation between the nausea and plasma vasopressin levels. 
Firstly, the ability of vasopressin to activate the neurons in the area postrema has 
been highlighted (Carpenter, 1990). Secondly, there is evidence that infusion of 
sufficiently high dose of vasopressin to the area postrema can induce nausea and 
vomiting in man (Thomford et al., 1975). Thirdly, marked elevation in plasma 
vasopressin has been demonstrated by the electrical stimulation of the central end of 
the abdominal vagus (Hawthorn et al., 1988). Fourthly, a more recent study 
demonstrates that both intravenous and intracerebroventricular injections of 
vasopressin also induce vomiting in Suncus miirimis (Ikegaya et al,, 2002). 
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However, the link between nausea and vasopressin is still far from proven, since a 
discrepancy has been reported in the human after the administration of ipecacuanha. 
Nussey et al (1988) demonstrated that ipecacuanha, as a powerful nauseogenic 
emetic stimulus, unexpectedly failed to elevate the plasma vasopressin levels. The 
precise reason for the discrepancy still remains unknown (Nussey et al., 1988). 
Further, the successful development of nausea in the idiopathic diabetes insipidus 
(DI) patients (whom are unable to secrete vasopressin in response to an osmotic 
stimulus) questions the direct correlation between nausea and vasopressin (Nussey et 
cd,, 1988). In fact, a similar query also arises from the recent study carried out by 
Grelot et al (2001), since nonpeptide vasopressin Via receptor antagonist, SR 49059, 
fails to inhibit cisplatin-induced emesis in piglets (Grelot et al., 2001). Moreover, 
species differences are evident with regard to vasopressin. Whilst a marked 
elevation in plasma vasopressin level occurs following a number of emetic stimuli in 
humans and monkeys, such a response is less obvious in rats. Interestingly, it is 
thought that another neurohypophyseal hormone, oxytocin, is produced more 
intensely in response to different emetic challenges (such as lithium chloride, copper 
sulphate and apomorphine) in rats (Verbalis et al, 1986). Therefore, the suitability 
of using different humoral matters to study nausea in different species should also be 
considered. 
With respect to the aforementioned studies, it seems that elevation of plasma 
vasopressin level results from a number of stimuli. To date, some explanations for 
this marked increase have been proposed. Vasopressin, which is an anti-diuretic in 
nature, may promote water retention against excessive fluid and ionic losses that may 
be induced by vomiting (Andrews & Davis, 1993b). Last but not ieast, its role in 
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establishing aversive memory against unfavourable stimuli has also been proposed 
(Andrews & Davis, 1993b; Nussey et al., 1988). 
There are currently some technical issues associated with experiments that assess 
plasma vasopressin levels. By virtue of the fact that blood samples of the 
experimental subjects should be collected to assay plasma vasopressin, the 
investigations may be impossible in small animals (like shrews), as changes in blood 
pressure or plasma osmolarity may occur (Fox, 1992). Besides, the real-time and 
continuous studying of plasma vasopressin is also problematic (Fox, 1992). Apart 
from these difficulties, it is also worth-noting that it remains to be demonstrated that 
there is a precise cause-effect relationship between vasopressin and nausea (Feldman 
etal, 1988). ^ 
1.3,5 Tachygastria 
It is well known that changes in gastrointestinal motility may affect mechanisms 
involved in nausea and vomiting. Gastric emptying and regurgitation occurring 
during vomiting are coordinated by subsequent contractions and relaxations of 
different smooth muscles along the alimentary canal. Similar to striated and cardiac 
muscles, contraction of the gastrointestinal smooth muscle is always preceded by a 
series of electrical activity (Davidson & Pilot, 1993) that involves the rhythmic 
waves of depolarization and repolarization of the smooth muscles cells, controlled by 
a pacemaker area in the bowel. In spite of the fact that this electrical activity is 
always present and not directly related to muscle contractions, it does determine the 
spatial and temporal organization of the gastric contractions (Verhagen et al., 1999). 
In humans, this basal electrical rhythm (BER, also denoted as slow wave, pacesetter 
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potential or electrical control activity) is approximately 3 and 5 cycles per minute in 
the stomach and duodenum respectively (Davidson & Pilot, 1993). In dogs, the BER 
is roughly 5 cycles per minute (Stem et al., 1987). The relationship between 
tachygastria, which can be defined as the augmentation in frequency of the gastric 
myoelectrical activity to 4 to 9 cycles per minute (Stem et aL, 1987), and nausea 
should be further explored. 
Gastric myoelectrical activity is normally studied by electrogastrogram (EGG). 
Tachygastria was first observed in dogs (Kelly et al,, 1972). Its relationship with 
idiopathic nausea and vomiting and gastric stasis were then reported in humans 
(Telander et cd., 1978; You et aL, 1980). In 1985, Stem et al. attempted to study the 
relationship between tachygastria and motion sickness in humans. Fourteen, out of 
21 subjects, exhibited tachygastria (5-8 cycles per minute) together with symptoms 
of motion sickness (based upon nausea, salivation, dizziness and/or warmth); no 
tachygastria was reported in the 7 asymptomatic subjects. Interestingly, a temporal 
correlation between tachygastria and the onset of motion distress was observed. In 
the study, the tachygastria that occurred in symptomatic subjects emerged 
approximately 5 minutes after the motion stimulus and 1 minute prior to the 
existence of symptoms (Stem et al., 1985). In fact, such a strong temporal link was 
confirmed by a follow-up study in 1987 (Stem et al., 1987). Although a positive 
correlation between tachygastria and motion sickness has been demonstrated in these 
studies, contradictory findings was also observed in 1997. Unexpectedly, only 1 
nauseated subject, out of 8，exhibited tachygastria in response to a motion stimulus 
(Kieman et al., 1997). The reason for this discrepancy is still unknown, but it may 
- due to the possibility that the existence of nausea may occur in the absence of gastric 
myoelectrical activity changes. Besides, the severity of nausea induced by the 
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different conditions of the motion challenge may account for the discrepancy 
(Kieman et al., 1997). 
Whilst it is indicated that tachygastria may occur during nausea, the exact neural 
mechanism is still unknown. However, the involvement of catecholamines, 
acetylcholine and P-endorphin have been suggested (Stem et al., 1985; Stern et al, 
1987; Tonato et al, 1993). 
In studying gastric myoelectrical activity, EGG, together with certain technical 
modifications and computer interventions, has been widely used. Although the 
noninvasiveness of the EGG measurement may be advantageous, some technical 
considerations should be considered. For example, the position and the surface area 
of the cutaneous electrodes may induce discrepancies in EGG measurement, ancfthe 
subjects' movement and respiration may also induce artifacts (Verhagen et al,, 
1999). 
Although some close correlation between tachygastria and nausea has been 
suggested, it is still impossible to identify their cause-effect relationship precisely. 
Therefore, the suitability of using tachygastria as a marker of nausea is still far from 
proven (Tonato et al,, 1993). 
1.3.6 Locomotor Activity 
In 1966, Eskin and Riccio demonstrated that the spontaneous locomotor activity in 
rats was attenuated by the vestibular stimulation (Eskin & Riccio, 1966). Apart from 
this, radiation treatment also found to reduce the spontaneous locomotor activity in 
ferrets (King et al., 1990) and mice (Landauer et al., 1988). In addition to these 
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examples, up to now, there are still few numbers of studies that have been targeted 
for investigating the direct correlation between nausea and locomotor activity in 
animals. Instead, the spontaneous locomotor activity in animals has mostly been 
used as a tool in studying the possible sedative effect of a particular anti-emetic (e.g. 
cannabinoid receptor agonists, WIN 55,212-2 and HU 210 (Darmani, 2001; Ferrari et 
al,, 1999)). However, it is still not known if there is a direct correlation between 
nausea and locomotor activity. 
1.4 Markers of Neuronal A ctivity 
k4.1 General Comments 
In many studies, scientists have been interested in the physiological significance of 
particular types of cells, and their roles in different pathways. Traditional methods 
for studying neuronal activity include t h e � q - d e o x y g l u c o s e autoradiographic 
technique, the cytochrome oxidase histochemical technique and the hexokinase 
histochemical technique. All these techniques have advantages and limitations (see 
Table 1.6). 
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Table 1.6 Summary of traditional ways for studying neuronal activity. 
Method Principle of action Advantage Disadvantage 
['^C]-deoxyglucose 2-deoxyglucose (2DG) is a primary Useful method Technically 
autoradiographic energy source in tissues. The in earlier times difficult 
technique accumulation of [丨4c]-2DG-6-
phosphate, as a phosphorylation 
product of ["C]-2DG, is measured by 
autoradiography. 
Cytochrome oxidase The activity of cytochrome oxidase, Straightforward Limited to 
histochemical which is an oxygen-activating enzyme and chronic study 
technique in cells, is analyzed by its action in inexpensive only 
oxidizing cytochrome C, which is 
then measured by histochemistry on 
the visible oxidized 
diaminobenzidine. 
Hexokinase Hexokinase is an enzyme involved in Straightforward Limited to 
histochemical the glycolytic pathway. Hexokinase and chronic study 
technique activity, which indicates the cellular inexpensive only 
metabolic activity, is quantified by  
densitometry in the areas of interest.  
Indeed, it is clear that all the aforementioned techniques are useful in studying 
neuronal activity (see Table 1.6). However, each technique is limited by either 
technical problems or that they are only relevant to chronic experimental protocols. 
These limitations indeed facilitate the development of a new method that involves 
the immediate-early gene (e.g. c-fos) molecular biology. 
1.4,2 c-fos Expression as a Marker of Neuronal Activity 
1,4.2.1 What is c-fos? 
c-fos is an immediate early gene (lEG). It can be activated by a variety of 
circumstances, ranging from physiological (e.g. growth factors, neurotransmitters, 
tumor promoters), physical (e.g. electrical stimulation, sensory stimuli) and 
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pharmacological (e.g. nicotine, oxotremorine) stimuli. Immediate early genes 
(lEGs) are also called primary response genes (Herschman, 1991). In response to 
stimuli, the genes are rapidly and transiently activated at the transcriptional level. In 
most cases, the mRNA and protein products of lEGs have very short half-lives. The 
mRNA and protein products of lEGs normally returns to basal minimal levels 
immediately after they have finished their roles in signal transduction. In fact, the 
gene product of c如，and also other immediate early genes, do have regulatory 
functions. Most of them are actually transcription factors of other genes, mainly the 
late response genes (Misra, 1994). This is perhaps one of the mechanisms 
responsible for long-term adaptive changes that occurs following wide range of 
stimuli (Figure 1.1) 
Figure 1.1 Schematic representation of gene expression cascade (Misra, 1994). 
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Apart from being classified as an immediate early gene, c-/os is also a proto-
oncogene. Oncogenes were first described as the genetic information responsible for 
the induction of neoplasia by RNA tumor viruses: c-/os is actually the counterpart of 
the viral oncogene v-fos (Van Beveren et al” 1983). 
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The Q-fos gene is a member of the /ay-related genes family. It encodes a nuclear 
protein, Fos, which is about 55kDa in size (Morgan et al., 1986). Fos tends to 
dimerize with another immediate gene product, Jun. This dimerization leads to the 
formation of the transcription factor AP-1 (Curran et al, 1982), which then binds to 
AP-1 sites in some other cellular genes (e.g. the late response genes) for further 
activation and then long-term changes. The dimerization of Fos and Jun is based on 
a specific structural motif，the leucine repeat (or "leucine zipper"). The leucine 
repeat consists of four to five leucine residues, which are regularly spaced at seven-
amino acid intervals (Landschulz et aL, 1988). Despite of the importance of leucine 
repeat in the dimerization of Fos and Jun in preparing the AP-1 complex, some other 
proteins may also exist as accessory factors. These include at least one Jun-related 
protein, Jun B (Ryder et al., 1988), and various Fos-related antigens of unknown 
function (Bohmann et al., 1988). 
Although the leucine repeat is of great significance in dimerizing Fos and Jun and 
forming the AP-1 complex, it is not directly involved in the DNA binding of the 
Fos/Jun complex to the AP-1 binding site (Turner et aL, 1989). Instead, studies have 
found that a novel DNA binding domain in Fos is involved. The domain mentioned 
is a region of protein that is rich in basic residues and is adjacent to, but distinct 
from, the leucine repeat of Fos. 
1.4.2.2 Regulation of c-fos Expression 
The basal level of expression of c-fos mRNA and protein is normally low. 
However, following a stimulus, c-fos gene expression will be up-regulated in a fast 
manner. Generally, a peak increase in c-fos mRNA occurs approximately around 30-
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45 minutes after stimulation (Muller et al., 1984). After this, the mRNA level 
decrease rapidly with a half-life of about 12 minutes. In contrast to the Q-fos mRNA, 
the Q-fos gene product，Fos, has peak increase detectable approximately around 1-2 
hours after the stimulation. Fos then decreases to basal level by 6-8 hours (Curran et 
al, 1984; Muller et al, 1984; Sonnenberg et al, 1989). 
As mentioned just above, the z-fos gene is expressed after a stimulus is applied. This 
up-regulatory process very much relies on two gene elements, which both lie in the 
initiation site for z-fos mRNA synthesis. They are the calcium response element and 
the serum response element, respectively. 
1,4.2.2.1 Calcium Response Element 
The calcium response element (CaRE) is located 60 nucleotides from the 5，initiation 
site for c-fos mRNA synthesis (Sheng et al., 1990). It is activated and responds to 
the influx of calcium ions, which transverse specialized channels embedded in the 
plasma membrane. In neurons, calcium ions enter by at least two types of calcium 
ions channels: voltage sensitive calcium channels (VSCCs) and N-methyl D-
aspartate (NMDA) receptors. The consensus sequence of calcium response element 
(CaRE) is -TGACGTTT- (Montminy et al., 1986). Constitutively bound to the 
calcium response element (CaRE) is the calcium response element binding protein 
(CREB), which actually acts as a positive transcriptional factor by phosphorylation at 
the serine 133 site (Sheng et al” 1990). The only result of this sequence of events is 
that o f OS gene expression is initiated, as the bound calcium response element is 
- located at the initiation site for the c-fos mRNA synthesis. 
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4.2.2.2 Serum Response Element 
The serum response element (SRE) is a gene element, other than the calcium 
response element, that can regulate the expression of c-fos gene upon stimulation. 
The serum response element (SRE) can be regarded as the protein-binding site 
required for the induction of Q-fos expression by serum and growth factors 
(Treisman, 1992). It is 22 bp in length and located 310 bp upstream from the 
initiation site of c-fos mRNA synthesis. Its activation is based on the binding of the 
major SRE binding protein, the serum response factor (SRF) (Treisman et al., 1992). 
The serum response factor (SRF) is a 508 amino acid nuclear protein (Norman et al., 
1988). It binds to the serum response element (SRE) as a dimer and contains a novel, 
but not yet fully characterized DNA binding domain that is highly conserved among 
SRF-related proteins. Although the DNA binding domain of SRF is not yet entirely 
characterized, it is reported that the minimal binding sequence for the serum response 
factor (SRF) is the CC(A/T)6GG inner core of the serum response element (SRE) 
(Rivera et al, 1990). 
1.4.2.3 Types of Receptors Involved in c-fos Expression 
In fact, a variety of stimuli that can activate c-fos expression mediate through the 
stimulation of receptors. Major receptors, upon stimulation, that affect c-fos 
expression include tachykinin receptors, 5-hydroxytryptamine (serotonin) receptors, 
nicotinic and muscarinic acetylcholine receptors, dopamine receptors and glutamate 
receptors. Thus, it may be possible to map unknown pathways in the brain following 
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activation by emetic stimuli, since a majority of receptor systems can be detected to 
have a role in Fos production (see below). 
To date, there are 3 well-accepted subtypes of tachykinin receptors, namely NKj, 
NK2 and NK3 receptors. Yip and Chahl (2000) demonstrated that substance P, which 
is a tachykinin receptor agonist that preferentially binds to NKi receptor, induced c_ 
fos expression in extensive areas in guinea pig brains upon receptor activation (Yip 
& Chahl., 2000). More interestingly, this z-fos expression is inhibited by the 
administration of NK! and NK3 receptors antagonists, SR140333 and SR 142801 
respectively (Yip & Chahl., 2000). Apart from this evidence, substance P also 
induces c-fos expression in certain rat brain areas related to the cardiovascular and 
丨� neuroendocrine reactions, which can actually be prevented by the NKi receptor 
‘ antagonist, RP 67580 (Spitznagel et al., 2001). On the other hand, neurokinin B，a 
NK3 receptor agonist, also induces o-fos expression in certain rat brain areas 
involving the regulation of blood pressure and water homeostasis (Spitznagel et al” 
2001). In another study, the NK3 receptor agonist, senktide, also elevates c-fos 
expression in certain brain areas in the rat, including the medial nucleus of the 
solitary tract, hypothalamus and the amygdala (Smith et al,, 2000). 一 
There are altogether 7 major classes of 5-hydroxytryptamine (5-HT) receptors now, 
classified according to transduction mechanisms and second messengers. There are 
sufficient evidences to prove the involvement of 5-HT receptors in modulating the c-
fos expression. “ Gresch et al. (2002) demonstrated that the 5-HT2A receptor 
antagonist, MDL 100907, completely blocked the lysergic acid diethylamide (LSD)-
induced c-fos expression in the medial prefrontal cortex and anterior cingulate cortex 
(Gresch et al., 2002). The 5-HT3 receptor antagonist, granisetron (BRL 43694) and 
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tropisetron (ICS 205930), also blocked cisplatin- (Reynolds et al., 1991) and X-ray 
irradiation- (Yamada et al., 2000) induced c-/os expression in the nucleus tractus 
solitarius respectively. Another 5-HT3 receptor antagonist, MDL 72222, also 
completely blocks amphetamine-induced striatal c-/os expression (Geneva et al, 
1998). Apart from the involvements of the 5-HT2A and 5-HT3 receptors, Neumaier et 
al. (2001) also highlighted the capability of the 5-HT7 receptor antagonist, pimozide, 
in preventing the 8-OH-DPAT-induced c-fos expression in rat forebrains (Neumaier 
et al., 2001). 
Apart from the aforementioned tachykinin and 5-HT receptors, muscarinic and 
nicotinic acetylcholine receptors are also found to be involved in c-fos expression. 
Greenberg et al (1986) demonstrated that c-fos expression is increased by the 
administration of nicotinic receptor agonists, such as nicotine and l,l-dimethyl-4-
phenyl-piperizinium iodide (DMPP), but reduced by the antagonist, mecamylamine. 
On the other hand, c-fos expression is also elevated by muscarinic receptor activation 
through the administration of the muscarinic receptor agonist, oxotremorine. 
Moreover, the involvement of muscarinic receptors is further confirmed by the 
reduction of oxotremorine-induced c-fos expression by the administration of atropine, 
the muscarinic antagonist (Greenberg et al, 1986). 
Glutamate (Glu) is a major excitatory neurotransmitter in nervous systems, with a 
significant role in primary afferent neurotransmission and nociception. Glutamate is 
known to mediate its action through both ionotropic (NMDA, AMPA, Kainate) and 
metabotropic receptor (mGluR) systems. There is evidence to support a glutamate 
receptor involvement in c-fos expression. Apart from the ability of the AMPA 
receptor antagonists, CNQX and NBQX, in reducing capsaicin-induced c-fos 
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expression in the trigeminal nucleus caudalis (Mitsikostas et al, 1999)，the NMDA 
receptor antagonist, MK-801, also has a dose-dependent action to reduce c-fos 
expression induced by capsaicin (Mitsikostas et al., 1998). 
To date, there are altogether 5 subtypes of dopamine receptors being classified, 
ranges from D] to D5. The involvement of dopamine receptors in Q-fos expression 
can be recognized from the fact that morphine-induced striatal c-fos expression is 
inhibited by SCH23390 and SCH39166, which are actually dopamine Di receptor 
antagonists (Sharp et al., 1995). 
Table 1.7 Effects of receptors' ligands on Q-fos expression.. 
Effect on c-fos 
Substances Receptor t h a ’ Agonist/ expression References 
act on Antagonist (Activation: + r^eierenceb 
Inhibition: -) 
Substance P NK, Agonist + Yip et al., 2000 
Spitznagel et al., 2001 
SR 140333 NK, Antagonist - Yip et al., 2000 
RP 67580 NK, Antagonist - Spitznagel e/ al., 2001 
CP-99994 NK, Antagonist - Shepheard et al., 1995 
SR 142801 NK3 Antagonist - Yip et al., 2000 
Neurokinin B NK3 Agonist + Spitznagel e/ aL, 2001 
Senktide NK3 Agonist + Smith et al., 2000 
MDL 100907 5-HT2A Antagonist - Gresch et al., 2002 
Granisetron 5 -HT3 Antagonist - Reynolds et aL, 1991 
Tropisetron 5-HT3 Antagonist - Yamada et al, 2000 
MDL 72222 5-HT3 Antagonist - Genova a/., 1998 
Pimozide 5-HT7 Antagonist - Neumaier et al., 2001 
Nicotine Nicotinic Agonist + Greenberg et al., 1986 
DMPP Nicotinic Agonist + Greenberg et aL, 1986 
Mecamylamine Nicotinic Antagonist - Greenberg et al., 1986 
Oxotremorine Muscarinic Agonist + Greenberg et aL, 1986 
Atropine Muscarinic Antagonist - Greenberg et aL, 1986 
MK-801 NMDA Antagonist - Mitsikostas et al., 1998 
Sharp et al., 1995 
CNQX AMPA Antagonist - Mitsikostas et aL, 1999 
NBQX AMPA Antagonist - Mitsikostas et al., 1999 
SCH23390 Dopamine D, Antagonist - Sharp et al., 1995 
SCH39166 Dopamine D � Antagonist - Sharp et al,, 1995 
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L4丄 4 Feasibility of Using c-fos Expression as Marker of Cellular Activity 
As previously mentioned，c-fos mRNA and protein levels in cells are low in normal 
cases. Once stimulation is applied, the c-fos gene expression inside cells will be 
elevated. c-/ay mRNA elevation usually peaks at 30-45 minutes after the stimulation, 
while the Fos protein peaks at about 1-2 hours (Muller et aL, 1984). All these criteria 
make the tracing of c-fos expression level suitable to be used as a metabolic marker 
of neuronal activity. It can be seen above that c-fos is expressed following activation 
of receptor systems that are known to be involved in the emetic reflex 
Tracing c-fos expression is normally carried out by immunohistochemical staining. 
An antibody that is specific to the protein Fos is applied for probing the c-fos gene 
product. As a matter of fact, the antibody's specificity towards the protein Fos is the 
critical step of the entire method. 
1.4.2.5 Identification of Emetic Pathway by c-fos Imm unoh istoch em istry 
In 1991, Reynolds et al. demonstrated c-fos expression in the nucleus tractus 
solitarius and the area postrema after cisplatin administration, indicating their active 
roles in the emetic reflex (Reynolds et al., 1991). Whilst unilateral vagotomy failed 
to affect cisplatin-induced emesis, it did reduce the c-fos expression in the nucleus 
tractus solitarius (but not in the area postrema) ipsilaterally. More interestingly, 
although the 5-HT3 receptor antagonist, granisetron, mimicked the effect of 
vagotomy on c-fos expression, it also completely prevents the cisplatin-induced 
- emesis. Apart from the highlighted vagal-dependent role of nucleus tractus solitarius 
and the 5-HT3 receptor involvement in the emetic reflex, the feasibility of using o-fos 
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immunohistochemistry in studying the emetic mechanisms was clearly demonstrated. 
In fact, there are also some other studies carried out in an attempt to delineate the 
emetic reflex, by using the c-fos immunohistochemistry, soon after the publication of 
Reynolds et al. (1991) (Ariumi et aL, 2000; Yamada et al., 2000; Zaman et al” 
2000). 
Among these studies, Zaman et al (2000) demonstrated that loperamide, a centrally 
acting |Li and 5 opioid receptor agonist, induces c-fos expression in the nucleus tractus 
solitarius. Interestingly, CP-99,994 was active to prevent the emesis but it failed to 
affect the c-fos expression in the brainstem. This intriguing finding raises interests in 
identifying some others brain areas (e.g. those in the forebrain) that may be involved 
in the emetic mechanism. t 
[ 
L5 Aims & Objectives 
At present, there is much information available about the brainstem mechanisms 
involved in the control of emesis. Perhaps the most intensively studied brain areas 
include the area postrema (AP), nucleus tractus solitarius (NTS) and the dorsal motor 
nucleus of the vagus nerve. Indeed, several important anti-emetic drugs (including 
the tachykinin NKi receptor antagonists) probably work by having an action in these 
brain areas. However, whilst the mechanisms involved in retching and vomiting 
have been studied extensively, the mechanisms involved in nausea are less defined. 
Certainly, nausea is a distressing side effect of many drug treatments (including 
chemotherapy) or illnesses and further investigations into its control are warranted. 
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Several animal species are used in pre-clinical anti-emetic research. Assessing the 
ability of a new drug to reduce retching and vomiting is relatively straightforward in 
animals and man. However, nausea is a rather subjective experience/sensation and it 
is therefore difficult to be studied in animals. Although several putative measures of 
nausea have been proposed, most of them (e.g. lip licking and salivation) can be 
observed in decerebrate/anaesthetised animals (Davidson & Pilot, 1993; Watson et 
al., 1995). Therefore, some of the behaviours could be expressed as a consequence 
of activating brainstem areas to result in vomiting, rather than being expressed as a 
consequence of activating brain areas involved in nausea that are presumably located 
in the forebrain. 
The primary aim of the present studies, therefore, was to more directly investigate an 
‘ involvement of forebrain areas involved in emesis control using the technique of c-
fos immunohistochemistry. With regard to anti-emetic research, the technique has 
been used successfully to identify brainstem areas involved in emesis control in 
animals with the vomiting reflex (Reynolds et al” 1991; Zaman et al” 2000); it has 
also been used to study the forebrain areas involved in conditioned taste aversion 
induced by emetic treatments in rats (Schafe et al” 1998; Schafe et al,, 1996). The 
studies would be the first to identify the forebrain areas that may be involved in 
emesis control in a species with the vomiting reflex (i.e. the ferret) that may provide 
information that may be considered relative to mechanisms involved in nausea. The 
studies may therefore provide a relatively simple model to predict if a candidate drug 
can prevent emesis and changes in forebrain activity (assessed by o-fos) that could be 
analogous to a potential to reduce the sensation of nausea. 
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The secondary aim of the studies was to monitor animal behaviour during emesis 
since some of the drug treatments could potentially have effects in the brain that may 
be unrelated to actions in the emetic reflex. This is a potential complication of the 
studies that has not been considered in detail by other investigators. Therefore, it 
was anticipated that all of the behavioural data could be correlated to potential 
changes in c-fos expression to avoid inadvertently misinterpreting the data as being 
only relevant to an action on the emetic reflex. The studies examined z-fos 
expression at 120 min post the administration of cisplatin. This time period is in 
between the sacrifice time used by others (range 60-195 min) to studies the emetic 
reflex (Ariumi et aL, 2000; Boissonade et al, 1996; Reynolds et al., 1991). An 
earlier, rather than later sacrifice time was selected so that any potential changes in c-
fos expression may be more relevant to initial behavioural changes that may be more I 
relevant to nausea, rather than as being predominantly expressed in the course of 
increased physical activity occurring during retching and vomiting. 
The studies also used Suncus murinus as a second species to monitor the effect of 
drug treatment on behaviour. The behavioural activity of Suncus murinus is much 
different from the ferret following treatment with emetic drugs and has not been 
characterized previously. It was anticipated that these studies could identify putative 
measures of nausea in this species and that the studies would complement the ferret 
work. During these studies, it was possible to investigate the action of emetic drugs 
on behaviour at sub-threshold doses and at doses that are emetic. This was done in 
attempt to characterize behaviour that may be more relevant to the animals 
experiencing nausea, rather that to characterize behaviour that is the result of the 
animals' pattern of activity during emesis that may obscure any subtle changes in 
behaviour due to nausea. 
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The above investigations were considered important in the light of the recent 
development of the tachykinin NK! receptor antagonists as anti-emetic drugs. 
Several of these compounds clearly antagonize retching and vomiting induced by a 
wide variety of emetic stimuli. However, if the compounds do not prevent emesis by 
more than 80 % in animals, the latency to the first episode of retching and or 
vomiting is not altered (Gardner et al, 1996; Rudd et al., 1999b). This is in contrast 
to the activity of the S-HTs receptor antagonists that can antagonize emesis and delay 
the onset of retching and vomiting (Tattersall et al., 2000). This may be related to 
the site of action of the drugs to prevent the emetic response: NKi receptor 
antagonists are presumed to work at a convergence point in the emetic reflex, close 
to, or at the vomiting centre. S-HTs receptor antagonists may antagonize emesis by 
blocking receptors at the start of an afferent input to the vomiting centre in addition 
to an action at the level of the NTS. It is therefore possible that NKi receptor 
antagonists may not be preventing information reaching the forebrain that may result 
in the sensation of nausea and this may be the case given the failure of some NK] 
receptor antagonists to prevent motion-induced nausea in man (Reid et al” 2000; 
Reid et al., 1998). However, in other studies against cisplatin-induced delayed 
emesis, the NK! receptor antagonists improve the control of nausea and emesis 
(Campos er al； 2001; Hesketh et aL, 1999; Navari et al,, 1999). It is not known if 
there are multiple sites of NKi receptors that are being activated during 
chemotherapy-induced emesis (i.e. some receptors on the early afferent inputs, in 
addition to the sites in the brainstem) that may account for the improved control of 
nausea seen following treatment with NK] receptor antagonists. -
In the present studies, CP-99,994 was selected as a well characterized reference NKi 
receptor antagonist to investigate if they could prevent emesis and potential 
40 
__... Chapter 1 - Introduction 
emetogen-induced increases in c-fos expression in the brainstem and forebrain areas 
of the ferret and the emetogen-induced changes in the behaviour of both the ferret 
and Suncus murinus. The emetogens studied were cisplatin, apomorphine, nicotine 
and copper sulphate and the mechanisms involved have been well characterized. 
These studies were compared with ondansetron and domperidone, anti-emetics 
known to be capable of antagonizing both emesis and nausea in man (De Mulder et 
al., 1990; Polubiec et ai, 1992; Ruff et al., 1994). It was hoped that the studies might 
shed light on the forebrain areas involved in emesis to provide new animal models to 
evaluate simultaneously if drugs have a potential to reduce both nausea and emesis in 
man. 
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CHAPTER 2 METHODS 
2,1 Animals 
2.1.1 Ferrets 
Castrated albino or fitch male ferrets, weighing between 1 kg — 2.5 kg, were used in 
the studies. They were obtained from a reputable breeder in New Zealand and were 
housed in a temperature-controlled room in the Laboratory Animal Services Centre, 
The Chinese University of Hong Kong, at 24±1 °C. Artificial lighting was provided 
between 0600 to 1800 h, with humidity being maintained at 50士5 %. Water and dry 
pelleted cat chow (Feline Diet 5003, PMI® Feeds, St. Louis, U.S.A.) were provided 
ad libitum. All experiments were conducted under the licence provided by the 
Government of the Hong Kong SAR and the Animal Research Ethics Committee, 
The Chinese University of Hong Kong (AREC Ref: 00/025/ERG and CUHK 
4066/00M). 
2.1.2 Suncus murinus 
Female Suncus murinus (house musk shrew) were used in the s tud ies�They were 
originally from Taipei and were developed as a colony at the Central Institute for 
Experimental Animals Kanagawa, Japan. Breeding pairs were brought to Hong 
Kong in 1995. They were housed in a temperature-controlled room in the 
Laboratory Animal Services Centre, The Chinese University of Hong Kong, at 24士 1 
Artificial lighting was provided between 0600 to 1800 h, with humidity being 
maintained at 50士5 %. Water and dry pelleted cat chow (Feline Diet 5003, PMI® 
42 
Chapter 2 - Methods 
Feeds, St. Louis, U.S.A.) were provided ad libitum. All experiments were conducted 
under the license provided by the Government of the Hong Kong SAR and the 
Animal Research Ethics Committee, The Chinese University of Hong Kong (AREC 
Ref: 00/025/ERG and CUHK 4066/00M). 
2.2 Measurement of Animal Behaviour 
2.2.1 Experiment Design 
Generally, all animals were transferred to the laboratory holding room 4 days prior to 
any experimental investigation. Subsequently, all experiments were performed in an 
isolated behaviour room at 15土 1 |Lux and 21±1°C. The observation chamber was 
made of black perspex (50 cm x 50 cm x 50 cm) and was positioned on a table 55 cm 
above the floor. The experiment started when the animals were introduced into the 
observation chamber. The same observation chamber was used to investigate drug 
action in both species. It was cleaned with 75 % ethanol between each animal. 
2.2.2 Recording of Animal Behaviour 
Animal behaviour was recorded by an EthoVision Color Pro system (Version 2.3， 
Noldus Information Technology, The Netherlands) and by manual assessment. 
Essentially, the image of each animal was captured by an overhead camera 
(Panasonic WV-CP460/P model) coupled with a video recorder (Panasonic NV- -
FU620 model), which was in turn connected to a colour video monitor (Sanyo VMC-
8314P model). The analog video signal was converted to a digital video signal by a 
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frame grabber and calculations of movement made using the EthoVision software 
(Version 2.3) running on a personal computer (Dimension 4100, Dell) (Figure 2.1). 
Figure 2.1 Schematic diagram showing the process of recording of animal 
behaviour. 
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2.2.3 Calibration of Equipment Used to Record Spontaneous Locomotor Activity 
The EthoVision Color Pro system calculated the distance between two points in 
pixels, by which all the behavioural parameters were measured. In order to convert 
the data to real values (e.g. centimeters), calibration of the system was required. The 
calibration procedure involved classifying a defined measurement to the computer 
software (i.e. the dimensions of the observation chamber in the present studies). 
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Repeated measuring from different edges of observation chamber was performed to 
obtain a more consistent calibration of the system. 
After calibration of the system, the software settings for detecting objects (i.e. ferrets 
or Suncus murinus) were also optimized. This was performed by adjusting the 
contrast and brightness sensitivity, and by use of custom erosion filter to subtract the 
animals' tails, so as to obtain a sharp image of the animals. These calibration 
procedures were performed for both species. 
After calibration, the programme calculated the distance travelled (summation of 
both forward and backward movement) and the velocity of movement of the animals 
automatically in each experiment. 
“ • 
2.2.4 Behaviour Recorded by the Observer 
In addition to measuring spontaneous locomotor activity, the temporal profile of 
emesis was manually recorded. Due to the species differences, the number of retches 
plus vomits and the latency to the first retch or vomit were recorded in ferrets, 
whereas the number of episodes of emesis and the latency to the first episode of 
emesis were recorded in the Suncus murinus. Emesis was characterized by rhythmic 
abdominal contractions which are either associated with the oral expulsion of solid or 
liquid material from the gastrointestinal tract (i.e. vomiting) or not associated with 
the passage of material (i.e. retching movements). Episodes of emesis were 
considered separate when an animal changed its location in the observation chamber 
or when the interval between retches and/or vomits exceeds 5 s. 
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In addition to emesis, the frequency of lip licking, curling up, burrowing, backward 
walking, rearing and defecation were also recorded. 
In both species, the manual recording of parameters was assisted and synchronized 
with the experimental tracking performed by the EthoVision Color Pro system. This 
was done by pressing pre-defined keys on the computer keyboard, to enable the 
software to "time-stamp" their occurrences. 
2,3 Administration of Drugs 
2.3.1 Ferrets 
r 
‘ 23.1.1 General Comments 
In order to reduce experimental artifacts which might be induced by exposing the 
animals to a novel environment, the ferrets were allowed to habituate in a perspex 
box (50 cm X 50 cm X 50 cm), that was identical to the experiment observation 
chamber. The animal was exposed to this chamber for 2 h at 24, 48 and 72 h prior to 
the start of the experiment. 一 
On the day of experiment, the ferrets under investigation were transferred to the 
perspex observation chamber (50 cm x 50 cm x 50 cm). The animals were allowed 
to habituate to the chamber for 15 min before the commencement of experiment. 
After the Habituation period, animal behaviour was recorded by the EthoVision 
Color Pro system for 30 min. Data obtained in this period represented the basal 
activity of the animals. 
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Drug administration was performed using commercially available syringes and 
needles (25G x Terumo® Syringe, Terumo Corporation, Tokyo, Japan). 
2.3.1.2 Drug Antagonism Studies 
In these studies, the emetogens used were: (1) cisplatin (10 mg/kg) and (2) 
apomorphine (0.25 mg/kg). 
After recording the basal activity, the ferrets were injected with ondansetron (1 
mg/kg), domperidone (1 mg/kg), CP-99,994 (10 mg/kg), or their respective vehicles 
(0.5 ml/kg), intraperitoneally. Animal behaviours were then recorded for a further 30 
min before the intraperitoneal injection of cisplatin (10 mg/kg) or its vehicle, or 
subcutaneous administration of apomorphine (0.25 mg/kg) or its vehicle. The 
animals were then observed for further 1-2 h. 
2.3,2 Suncus murinus 
2,3.2.1 General Comments 
On the day of experiment, Siincus murinus under investigation were transferred to a 
perspex observation chamber (50 cm x 50 cm x 50 cm). Animal behaviour was 
recorded by the EthoVision Color Pro system for 30 min to define the basal activity 
of the animals. 
Drug administration was then performed using commercially available syringes and 
needles (25G x Vs'', Terumo® Syringe, Terumo Corporation, Tokyo, Japan), except 
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those involving the injection of copper sulphate, which utilized an oral-dosing needle 
(modified from 18G x 3/2" Monoject 220 spinal needle, St. Louis, U.S.A.). 
2.3.2.2 Dose-Response Studies 
The emetogens that were studied included: (1) nicotine, (2) copper sulphate, and (3) 
cisplatin. In order to determine the doses that induced emesis and associated 
behaviours significantly in the Suncus murinus, their dose-response relationships 
were investigated. Furthermore, the potential dose-response relationship of 
antagonists (CP-99,994 and ondansetron) to affect behaviour was also studied. 
Therefore, after the recording basal activity, the animals were injected with nicotine 
(0-5 mg/kg, subcutaneousiy), copper sulphate (0-120 mg/kg, intragastrically), 
cisplatin (0-30 mg/kg, intraperitoneally), CP-99,994 (0-10 mg/kg, intraperitoneally 
or subcutaneousiy), ondansetron (0-3 mg/kg, subcutaneousiy)，or their respective 
vehicles. Animal behaviour was then recorded for a further 30-240 min. 
2.3.2.3 Drug Antagonism Studies 
In the nicotine and copper sulphate studies, the animals were injected with CP-
99,994 (0-10 mg/kg) or its vehicle (2 ml/kg) intraperitoneally after the recording of 
basal activities. Animal behaviour was then recorded for 30 min before they were 
injected with nicotine (0 and 5 mg/kg, subcutaneousiy), copper sulphate (0 and 120 
mg/kg, intragastrically), or their respective vehicles (2 ml/kg). The animals were 
then observed for a further 30 min. 
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In the cisplatin studies, the animals were injected with CP-99,994 (0-10 mg/kg), 
ondansetron (0-3 mg/kg) or their respective vehicles (2 ml/kg) subcutaneously, 30 
sec post cisplatin (0-30 mg/kg, intraperitoneally) administration after the recording of 
basal activity. Animal behaviour was then recorded for a further 4 h. 
The general protocol used for the behavioural studies of the ferrets and Suncus 
murinus are summarized in Figure 2.2. 
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2.4 c-fos Expression Studies in Ferret Brainstems 
2.4.1 Animals and Anaesthesia 
The behavioural investigations of the action of emetic and anti-emetic drugs in the 
ferret were complemented by studies of c-fos expression in the brainstem and 
forebrain. It should be noted that the c-fos technique has been extensively used to 
study z-fos expression in the brainstem. However, there are variations in the 
conditions of the reactions and differences in the reagents used by the previous 
investigators. The preliminary studies, therefore, mainly used brainstems from the 
cisplatin- or vehicle-treated animals in the behavioural studies to determine the 
optimal condition to map c-fos expression in the forebrain. All animals in this part of 
the investigations were deeply anaesthetized by sodium pentobarbital (40 mg/kg, i.p.) 
to enable in situ fixation of ferret tissues (see below). 
2.4.2 Perfusion and fixation 
After the animals were deeply anaesthetized, the skin was excised and the thoracic 
cavity was exposed. A needle (18G x r/2", Temmo® Needle, Terumo Corporation, 
Tokyo, Japan) was inserted into the left ventricle of the animals' heart, together with 
an incision made in the right auricle to drain the blood. The animal was then 
perfused with 300 ml of 0.9 % (w/v) saline, followed by 300 ml of 4 % (w/v) 
buffered paraformaldehyde (pH 7.4), using a perfusion pump (Masterflex, 1-100 
RPM, Cole-Parmer Instrument Company, Chicago, U.S.A.). The ferret brains were 
— then extracted and immersed in 4 % (w/v) buffered paraformaldehyde for 24 h, 
followed by the removal of dura under a dissection microscope (Stemi 2000-C, 
50 
Chapter 2 - M e t h o d s 
Zeiss, Germany). The brains were kept in 4 % (w/v) buffered paraformaldehyde 
until they were further processed for immunostaining. 
2.4.3 Dehydration of brains 
Prior to the immunohistochemical procedures, the ferret brains were dehydrated in 
30 % (w/v) buffered sucrose solution for 48 h. In order to increase the surface area 
for dehydration, each ferret brain was cut into blocks of four (see Figure 2.3) just 
before immersing in the sucrose solution. After the dehydration procedure, the brain 
blocks were immersed in O.C.T. (Tissue-Tek®, Sakura, U.S.A.), at 4。C, for 24 h. 
This was done to remove the sucrose solution from the sample surface. 
Figure 2.3 Diagram showing the sectioning of intact ferret brain into blocks of four 
before dehydration. 
——J-^4Blocks / Y ? ： ^ ' \ 
f \ 1 � , : , � f\ ' - A \ 
1... A \ r � D Block 4 ( w ； 
/ U Y \ f 
i 1 1 1 1 1 u u U 
V e n t r a l v i e w of f e r r e t D o r s a l v i e w o f f e r r e t V e n t r a l v i e w o f B l o c k 4 
bra in bra in 
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2.4.4 Embedding of tissue 
The dehydrated blocks of brain were then submerged in O.C.T., with the anterior end 
(for Block 4) or posterior end (for Blocks 1-3) orientated towards the bottom, using a 
mould that was made of aluminum foil. The preparation was cooled to 4°C for 24 h, 
and then frozen at -20°C for 24 h. The embedded blocks were then briefly frozen in 
liquid nitrogen before being stored in a freezer at -70°C. The careful cooling 
procedure was conducted to avoid cracking the blocks that might occur as a result of 
rapid changes of ambient temperature. 
2.4.5 Sectioning 
I 
The blocks were mounted on a microtome stage inside a cryostat (AS 620E, 
Shandon, U.S.A.) at -20 Sections were cut from the blocks at a thickness of 30 
|Lim. One in every three sections was mounted on glass slides (25 x 75 x 1 m m , 
SuperFrost® Plus, Menzel-Glaser, Germany), which were then stored at room 
temperature. 
2.4.6 Staining 
The avidin-biotin horseradish peroxidase procedure, using diaminobenzidine (DAB) 
as a chromogen, was applied in the current study. 
The sections, after air-drying at room temperature for 1 hour, were first washed 3 
times, with 0.1 M phosphate buffered saline (PBS). Each wash lasted for 5 min and _ 
was performed using an orbital shaker. To quench any endogenous peroxidase, the 
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sections were incubated with 5。/。hydrogen peroxide in methanol for 5 min at room 
temperature. After a transient wash with water, the sections were then washed 3 
times with 0.1 M PBS. Again, each wash lasted for 5 min. After washing, the 
sections were blocked in 1 % normal goat serum in 0.1 M PBS, with 0.3。/。(v/v) 
triton X-100, for 90 min at room temperature. The incubation of sections with the 
primary antibody (using dilution ratios as suggested by the suppliers: range 1:50 to 
1:500) was started immediately after the blocking step and it proceeded for 48 hours 
at 4。C. The sections were then washed for another 3 times (5 min each) with 0.1 M 
PBS and incubated with the biotinylated secondary antibody (which was specific to 
the primary antibody) in 0.1 M PBS, with 1 % (v/v) normal goat serum and 0.3 % 
(v/v) triton X-100 for 90 min at room temperature. The sections were again washed 
3 times with 0.1 M PBS (5 min each) and incubated with the avidin-biotin reagent 
complex for 90 min at room temperature。The sections were then washed another 3 
times (5 min each) with 0.1 M PBS and incubated with 20 % (w/v) D A B in 0.1 M 
PBS. Twenty seconds post the addition of DAB，5 jul of 35 % (v/v) hydrogen 
peroxide was then added. The enzymatic reaction was allowed to proceed for 3 min 
under gentle agitation. After rinsing under running water for 2 min, the sections 
were dehydrated in 70 % , 80 % , 90 % and 100 % (3 times) alcohol for 20 sec, 20 sec, 
90 sec and 1 min respectively. After three immersions in xylene (each immersion 
lasted for 2 min), the sections were mounted with coverslips (24 x 50 m m , La 
Fontaine, Germany), by using histological mounting medium (Permount®, Fisher 
Scientific, U.S.A.). 
After air-drying the slides at room temperature for three days, the sections were 
inspected for brown Fos positive cells, under the light microscope (Optiphot, Nikon, 
Japan). 
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The procedures of the c-fos expression study is summarized in Figure 2.4. 
Figure 2.4 Protocol for c-fos expression study. 
Anaesthesia �"^"imals were anaesthetized with sodium 
pentobarbital, 40 mg/kg, i.p. 
(0 Animals were transcardially perfused with 0.9 % ~ 
(w/v) saline &4% (w/v) buffered paraformaldehyde p f . o 
(2) Brains were extracted and immersed in 4 % (w/v) ^ CriUSlOn <X 
buffered paraformaldehyde, at 4 "C. for 24 h Fixatioil 
(V Dura was removed under dissection microscope 
� Brains was cut into blocks of 4 
Dehydration � Dehydrated in 20% (w/v) sucrose 
solution for 48 h 
(2) Immersed in O. C. T., at 4 "C, for 24 h ;-
(1) Brain blocks were embedded in O.C.T., at 4°C, for ~— “ 
24 h; then at -20°Cfor 24 h further Embedding 
Brain blocks were briefly frozen in liquid nitrogen 
(0 Brain blocks were sectioned in cryostat, 
Sectioninp^ at -20�C’ with thickness of 30fim 
(2) 1 in every 3 sections were mounted on 
— glass slides 
(V Slides were air-dried at R. T. for 1 h 
(2) Incubated with 5 % H2O2, at R. T., for 5 min 
(V Incubated with 1 % normal goat serum, at R. T.Jor 
90 min 
(4) Incubated with 1°A b, at 4 °C’ for 48 h 
fV Incubated with 2°Ab, at R. T.Jor 90 
min 
(6) Incubated with avidin-biotin complex, at R.T.for 90 Stainino^ 
mm 
(V Incubated with 20 % DAB (w/v) 
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(9) Slides were dehydrated in ascending alcohols & 
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l。Ab: Primary antibody 
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7 Antibodies used 
A variety of antibodies were investigated in the present studies. The species that the 
antibodies were raised against and the various dilution ratios used (as suggested by 
the respective suppliers) are listed in the table below. 
Table 2.1 Antibodies used in the current studies. 
Antibody Supplier Host Dilution 
— ratios used 
Sheep polyclonal antibody to Fos Sigma-AIdrich, Australia Sheep 1.100/1.500 
oncoprotein (OA-11-824A) 叩 
Sheep polyclonal antibody to c-fos Cymbus Biotechnology Sheen 1 -200 
oncoprotein (CBL-400) Ltd” U.K. P. 
^^^PrOol/elfAa^f body to c 如 Santa Cruz Biotechnology Goat 1:100/1:500 
oncoprotein (SC-52-G) Inc., U.S.A. 
Rabbit polyclonal antibody Oncogene Research Rabbit 1.100/1.500 
(lyophilized) (PC05L-10GUG) Products, U.S.A. 1.川。/1.500 
Rabbit polyclonal antibody to c-fos Santa Cruz Biotechnology, Rabbit 1.100/1.500 
oncoprotein (SC-52) Inc., U.S.A. 1.訓/1.500 
Mouse anti-c-fos oncoprotein monoclonal Novocastra Laboratories Mouse i-mo 
antibody (NCL-FOS) Ltd.，U.K. 
Mouse anti-c-/ay oncoprotein monoclonal Chemicon International, Mouse 1.50 
antibody ( M A B 1283) U.S.A. 
2.4.8 Positive Control Slides 
As difficulties were encountered in establishing Fos positive staining in the brain 
samples, Fos positive control slides of human colon carcinoma (Oncogene Research 
Products, U.S.A.) were purchased to confirm the viability of the aforementioned 
antibodies. -
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2.5 Experimental Design and Statistics 
2.5.1 Randomization of Treatments 
The sequence of treatments administered in these studies was randomized according 
to a standard Latin Square design. This was done to eliminate the effects of external 
factors (e.g. variation of equipment, fluctuation of ambient temperature and stress of 
handling) that might alter the experimental results. Table 2.2 details of how the 
Latin Square was implemented in an investigation involving six sub-sets of 
experiment and four doses of a particular drug (D。，D]，D2, D3). 
Table 2.2 Randomization protocol for the behavioural studies. 
Set of Treatment 
experiment A B c D 
1 D^ D^ 
2 D3 Do D , D2 
3 D2 D3 Do Di 
4 Di D2 Ds Do 
5 Do Di D2 D3 
6 Ds Do Di D2 
Collectively, twenty-four animals were randomized in the experiment. Due to the 
limitation of equipment described in these studies, only one animal could be dealt 
with at any one time. In the first set of experiments, animals that were administered 
Do were used first, followed by Di, then D2 and finally D3. In the subsequent sets of 
the experiment, the sequence of drug administration was arranged according to the 
protocol as shown in Table 2.2. 
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2.5.2 Statistics 
2,5,2.1 Ferrets 
The distance travelled (mean = 7195.0, standard deviation = 4832.0，KS distance = 
0.1685, n = 96, pooled data) of ferrets recorded during the 30 min Habituation period 
of present studies was not normally distributed (P二0.0086: Normality test, based on 
the Kolmogorov-Smimov test; GraphPad Prism version 4.0.0, GraphPad Software, 
San Diego, California, U.S.A.). For statistical purposes, it was Logio transformed 
and became normally distributed (mean = 3.761, standard deviation = 0.31, K S 
distance = 0.08504: Normality test: P>0.1); the Log,o transformed data was then 
analyzed using parametric tests (see below). Velocity of movement data (mean = 
2.762，standard deviation = 2.189, K S distance = 0.2075, n = 96, pooled data) of 
ferrets recorded during the 30 min Habituation period of present studies was 
normally distributed (P>0.1: Normality test, based on the Kolmogorov-Smimov test; 
GraphPad Prism version 4.0.0, GraphPad Software, San Diego, California, U.S.A.). 
The lip licking episodes (mean = 7.1, standard deviation = 6.902, K S distance = 
0.1633, n = 96, pooled data), the total number of curling up episodes (mean =1.417, 
standard deviation = 2.019, K S distance = 0.2415, n = 96, pooled data), the total 
number of burrowing episodes (mean = 2.167, standard deviation = 5.591, K S 
distance = 0.3639, n = 96, pooled data), the total number of backward walking 
episodes (mean = 1.490, standard deviation = 3.290, K S distance = 0.3253, n = 96, 
pooled data), the total number of rearing episodes (mean = 15.73, standard deviation 
=12.99, K S distance = 0.1421, n = 96, pooled data) and the total number of 
defecatory episodes (mean = 0.2396, standard deviation = 0.4529, K S distance -
0.4724, n = 96, pooled data) occurring during the 30 min Habituation period of — 
57 
g ^ a a — i i i i i s = = — ^ ― — p — Chapter 2 - Methods 
present studies was not normally distributed (PO.l: Normality test, based on the 
Kolmogorov-Smimov test; GraphPad Prism version 4.0.0, GraphPad Software, San 
Diego，California, U.S.A.)； it was not possible to Log,o transform the data. The 
retching and/or vomiting episodes data but not the latency data was considered to be 
normally distributed (based on a larger data-set of historical data, personal 
com�nication, J.A. Rudd). Differences between the distance travelled (Log.o 
transformed data) and the velocity (raw data) of the respective treatment groups was 
analyzed by a one-way analysis of variance ( A N O V A ) followed by a Fisher's P L S D 
test (StatView version 5.0.1, SAS Institute, Gary, North Carolina, U.S.A.). However, 
the data was also normalized, either to the basal activity of the animals recorded 
during the Habituation period, or to the activity of the animals recorded during the 
Pretreatment period. This was done because of the large differences in the individual 
behavioural profiles of some of the animals. Under such circumstances, the 
differences between treatment groups of the normalized data were analyzed by a one-
way A N O V A followed by a Fisher's P L S D test (StatView version 5.0.1, SAS 
Institute, Gary, North Carolina, U.S.A.). The emetic episodes data was only 
analyzed during the Test periods (i.e. following emetogens, or vehicle) and 
differences between treatment groups was also assessed by a one-way A N O V A 
followed by a Fisher's P L S D test (StatView version 5.0.1, SAS Institute, Gary, North 
Carolina, U.S.A.). The latency data was also only analyzed during the Test periods 
but by using a Kruskal-Wallis test followed by a Dunn's multiple comparison test 
(GraphPad Prism version 4.0.0，GraphPad Software, San Diego, California, U.S.A.). 
Where necessary, when an animal failed to retch or vomit, a latency value equal to 
the Test period observation time was used to perform the statistical analysis. The 
total lip licking, curling up, burrowing, backward walking, rearing and defecatory 
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episodes occurring during the Habituation, Pretreatment and/or Test periods were 
analyzed using a Kruskal-Wallis test followed by a Dunn's multiple comparison test 
(GraphPad Prism version 4.00, GraphPad Software, San Diego, California, U.S.A.). 
Results are expressed as the mean士s.e.mean unless otherwise stated. In all cases, 
difference between treatment groups were considered significant when P<0.05. 
2.5.2.2 Suncus murinus 
The distance travelled (mean = 8494.0, standard deviation = 4236.0, K S distance = 
0.2385，n = 227, pooled data) and velocity of movement data (mean = 16.2, standard 
deviation = 13.9, K S distance = 0.2385，n = 227，pooled data) of Suncus murinus : 
recorded during the 30 min Habituation period of present studies was normally 
distributed (P>0.1: Normality test, based on the Kolmogorov-Smirnov test; 
GraphPad Prism version 4.00, GraphPad Software, San Diego, California, U.S.A.). 
The retching and/or vomiting episodes data but not the latency data was considered 
to be normally distributed (based on a larger data-set of historical data, personal 
-communication, J.A. Rudd). Therefore, differences between the distance travelled 
(raw data) and the velocity (raw data) of the respective treatment groups was 
analyzed by a one-way analysis of variance ( A N O V A ) followed by a Fisher's P L S D 
test (StatView version 5.0.1，SAS Institute, Gary, North Carolina, U.S.A.). However, 
the data was also normalized, either to the basal activity of the animals recorded 
during the Habituation period，or to the activity of the animals recorded during the 
Pretreatment period. This was done because of the large differences in the individual 
behavioural profiles of some of the animals. Under such circumstances, the 
differences between treatment groups of the normalized data were analyzed by a one-
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way A N O V A followed by a Fisher's P L S D test (StatView, version 5.0.1, SAS 
Institute，Gary, North Carolina, U.S.A.). The emetic episodes data was only 
analyzed during the Test periods (i.e. following emetogens, or vehicle) and 
differences between treatment groups was also assessed by a one-way A N O V A 
followed by a Fisher's P L S D test (StatView version 5.0.1, SAS Institute, Gary, North 
Carolina, U.S.A.). The latency data was also only analyzed during the Test periods 
but by using a Kruskal-Wallis test followed by a Dunn's multiple comparison test 
(GraphPad Prism version 4.00, GraphPad Software, San Diego, California, U.S.A.). 
Where necessary, when an animal failed to retch or vomit, a latency value equal to 
the Test period observation time was used to perform the statistical analysis. Results 
are expressed as the mean士s.e.mean unless otherwise stated. In all cases, difference 
between treatment groups were considered significant when P<0.05. 
2.6 Drugs and Chemicals Used 
2.6.1 Drugs Used 
All information about the drugs used in the present studies were listed in Table 2.3. 
All drug doses in the current studies refer to the free acids or bases. 
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Table 2.3 Drugs used in the current studies. 
Drugs Supplier Solvent/Vehicle Dose range Injection volume 
Apomorphine Sigma-Aldrich, Sodium meta- 0-0.25 mg/kg 0.5 ml/kg (Ferret) 
hydrochloride Saint Louis, bisulphite (Ferret) 
U.S.A. solution 
Copper sulphate Riedel-Dehaen, Distilled water 0-120 mg/kg 2 ml/kg {Suncus 
pentahydrate Germany {Suncus m.) m.) 
Cisplatin David Bull Normal Saline 0-10 mg/kg 10 ml/kg (Ferret & 
(cis-Platinum (II)- Laboratories, (Ferret) (Ferrets) Suncus m.) 
Diammine Victoria, Australia 
Dichloride) (Ferret) 
Sigma-Aldrich, Acidic Saline, p H 0-30 mg/kg 
Saint Louis, 4 {Suncus m.) {Suncus m.) 
U.S.A. {Suncus 
m.) 
CP-99,994 Pfizer Inc., Central Distilled water. 0-10 mg/kg 0.5 ml/kg (Ferret) 
(2S, 3S)cis-3(2- Research Division, (Ferret & 
methoxybenzyl- Groton, U.S.A. Suncus m.) 2 ml/kg {Suncus 
amino)-2-phenyl m.) 
piperidine 





Nicotine ditartrate Sigma-Aldrich, Distilled water 0-5 mg/kg 2 ml/kg {Suncus 
Saint Louis, {Suncus m.) m.) 
U.S.A. ~ 
Ondansetron GlaxoSmithKline, Normal Saline 0-1 mg/kg 0.5 ml/kg (Ferret) 
hydrochloride U.K. (Ferret) 
dihydrate 
0-3 mg/kg 2 ml/kg {Suncus 
{Suncus m.) m.) 
Pentobarbital Alfasan, Woerden, 丨 40 mg/kg 丨 
sodium Holland - (Ferret) 
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2.6.2 Chemicals Used 
Table 2.4 summarizes the chemicals utilized for dissolving the drugs and for 
preparing the solutions used in the c-fos expression study. 
Table 2.4 Chemicals used in the present studies. 
Chemicals Supplier Solvent for  
dissolving 
3,3,-Diaminobenzidine Sigma-Aldrich, Saint Louis, U.S.A. Distilled water 
(3,3�’4,4’-Tetraaminobipheyl) 
D M S O (Dimethylsulphoxide) Sigma-Aldrich, Saint Louis, U.S.A. / 
Hydrogen peroxide 35 % Riedel-de Haen, Germany / 
Paraformaldehyde, Granular Electron Microscopy Sciences, Phosphate buffer 
Washington, U.S.A. 
Potassium Chloride B D H Laboratory, England Distilled water 
Potassium dihydrogen B D H Laboratory, England Distilled water 
orthophosphate 
Sodium Chloride Merck, Germany Distilled water 
Sodium dihydrogen phosphate Merck, Germany Distilled water 
di-Sodium hydrogen phosphate Merck, Germany Distilled water 
12-hydrate cryst. 
Sodium metabisulphite Riedel-de Haen, Germany Distilled water 
Sucrose (saccharose) Merck, Germany Phosphate buffer 
62 
= Chapter 3 - Results 
CHAPTER 3 RESUL TS 
3.1 Ferret 
3.1.1 The Effect of Ondansetron and CP-99,994 on Emesis and Locomotor Activity 
Changes Induced by Cisplatin in the Ferret 
The ferrets were highly active during the 30 min Habituation period: distance 
travelled was 5284土459.3 cm (pooled data, n二48) with an average velocity of 
2.9±0.3 cm/s (pooled data, n二48). Analysis of the raw data revealed that CP-99,994 
(10 mg/kg, i.p.) decreased the total distance travelled (P<0.05, Figure 3.1, C) and the 
velocity of movement (P<0.05-0.01, Figure 3.1, D) of animals during the 
Pretreatment period. Ondansetron (1 mg/kg, i.p.) also decreased the locomotor 
activity measures in one of the treatment groups during the Pretreatment period 
(P<0.05-0.01, Figure 3.1, C and D). Cisplatin (10 mg/kg, i.p.) was inactive to affect 
the total distance travelled (Figure 3.1, C) and the velocity of movement (Figure 3.1, 
D) during the Test period (P>0.05). However, cisplatin induced 39.8±17.1 retches + 
vomits (PO.OOl: Figure 3.1, B) following a latency of 99.4士4.8 min (—PO.OOl: 
Figure 3.1，A); the emetic action was totally prevented by both ondansetron and CP-
99,994 (PcO.OOl: Figure 3.1, B). 
The spontaneous locomotor activity data of the animals was also normalized to the 
respective activity of each animal recorded during the Habituation and Pretreatment 
periods. Using this approach, it was evident that ondansetron and CP-99,994 were 
inactive as single treatments to modify either the distance travelled or the average 
velocity of the animals during the 30 min Pretreatment period (P>0.05: Figure 3.2, 
— — ^ ― — — — 
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Al and A2). Ondansetron and CP-99,994 were also inactive to modify spontaneous 
locomotor activity if the Test data (collected for an additional 120 min) was 
normalized to the Habituation data (P>0.05: Figure 3.2, B1 and B2); cisplatin was 
also inactive, alone and in combination with ondansetron or CP-99,994 (P>0.05). 
However, significant differences could be detected between the treatment groups if 
the data obtained during the Test period (i.e. to include data from animals receiving a 
second injection of cisplatin or vehicle) was normalized to the activity of animals 
recorded during the Pretreatment period (Figure 3.2, CI and C2). The differences 
mainly related to the action of CP-99,994, alone and in combination with cisplatin: 
animals receiving CP-99,994 with vehicle or cisplatin were more active during the 
Test period, travelling approximately 110-260 % further, with 190-420 % increases 
in the velocity of movement than animals treated with vehicles, ondansetron or 
cisplatin (P<0.05-0。001: Figure 3.2, CI and 
The ferrets also exhibited other spontaneous behaviours during the experiments. 
Thus, during the Habituation period, there were 6.0±0.9 (n=42) episodes of lip 
licking, 2.9±0.9 (n=48) episodes of burrowing, 13.5±1.8 (n二48) episodes of rearing, 
~ 1.4±0.4 (n=48) curling up episodes, 1。8±0.6 (n=48) episodes of backward walking 
and 0.3±0.1 (n=48) episodes of defecation (Figure 3.3, A-F). There was some intra-
treatment group variability in the frequency of burrowing between animals that were 
scheduled to receive either ondansetron + vehicle and vehicle + cisplatin (P<0.05, 
Figure 3.3, C ) � b u t it was not possible to normalize the data sets because some 
animals had zero behavioural scores during this period. Analysis of data during the 
Pretreatment time revealed that CP-99,994 reduced significantly the number of 
episodes of lip licking compared to vehicle-treated animals (P<0.05，maximum 
reduction was 88.5 %: Figure 3.3, A). However，both ondansetron and CP-99,994 
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failed to significantly affect burrowing, rearing, backward walking activity, the 
frequency of defecation or the curling up frequency (P>0.05). During the Test 
period, animals receiving CP-99,994 and vehicle，or cisplatin, or vehicle and 
cisplatin, had more episodes of defecation than the group receiving ondansetron and 




Figure 3.1 The effect of ondansetron and CP-99,994 on emesis and locomotor 
activity changes induced by cisplatin in the ferret. Ondansetron (〇：1 mg/kg, i.p.), 
CP-99,994 (CP: 10 mg/kg, i.p.) or vehicle (V: saline or distilled water, 0.5 ml/kg, 
i.p.) were administered after a 30 min habituation period (Habituation period) and 
animals were observed for a further 30 min (Pretreatment period). Cisplatin (Pt: 10 
mg/kg) or vehicle (V: saline, 10 ml/kg) was then administered intraperitoneally and 
animals were observed for another 120 min period (Test period). Results represent 
the mean士s.e.mean of the total number of emetic episodes (plot B), the total distance 
travelled (plot C) and velocity of movement (plot D) occurring during the 
Habituation, Pretreatment and/or Test periods. Individual latencies to the first 
episode of retching and/or vomiting are shown as filled circles (plot A: horizontal 
lines on the latency plot represent the mean latencies of the respective treatment 
groups). The number of animals retching and/or vomiting out of the number of 
animals tested (RV/T) is also shown. For the latency data (plot A), significant 
� 
differences relative to the V + V treated animals are indicated as P<0.001， 
significant differences relative to the V+Pt treated animals are indicated as 
t卞卞P<0.001 (Kruskal-Wallis test followed-by a Dunn's multiple comparison test). For 
the emetic episodes data (plot B), significant differences relative to the V + V treated 
��SFC 
animals are indicated as P<0.001; significant differences relative to the V+Pt 
treated animals are indicated as 竹卞P<0.001 (one-way A N O V A followed by Fisher's 
PLSD test). For the spontaneous locomotor activity data (plots C and D), significant 
differences relative to the respective treatment groups are indicated as *P<0.05 or 
"P<0.01 (one-way A N O V A followed by Fisher's P L S D test). 
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Figure 3.2 The effect of ondansetron, CP-99,994 and/or cisplatin or respective 
vehicles on spontaneous locomotor activity as normalized to the basal activity (plots 
Al, A2 and Bl, B2) or normalized to the activity of the ferret during the 
Pretreatment period (plots CI and C2). Ondansetron,(〇：1 mg/kg, i.p.), CP-99,994 
(CP: 10 mg/kg, i.p.) or vehicle (V: saline or distilled water, 0.5 ml/kg, i.p.) was 
administered after a 30 min Habituation period (i.e. to define the basal activity of the 
animals) and animals were observed for a further 30 min (i.e. representing the 
activity of the animals during the Pretreatment period). Cisplatin (Pt: 10 mg/kg) or 
vehicle (V: saline, 10 ml/kg) was then administered intraperitoneally and animals 
were observed for another 120 min period (i.e. representing the activity of the 
animals during the Test period). Results represent the mean士s.e.mean of 8 
I 
determinations. Significant differences between the respective treatment groups are 
indicated as *P<0.05, **P<0.01 or '**P<0.001 (one-way A N O V A followed by 
































































































































































































































































































































































































































































































































































Figure 3.3 The effect of ondansetron, CP-99,994 and/or cisplatin on the general 
behaviour of the ferret. Ondansetron (〇�1 mg/kg, i.p.), CP-99,994 (CP: 10 mg/kg, 
i.p.) or vehicle (V: saline or distilled water, 0.5 ml/kg, i.p.) were administered after a 
30 min habituation period (Habituation period) and animals were observed for a 
further 30 min (Pretreatment period). Cisplatin (Pt: 10 mg/kg) or vehicle (V: saline, 
10 ml/kg) was then administered intraperitoneally and animals were observed for 
another 120 min period (Test period). Results represent the meanis.e.mean of the 
total number of lip licking episodes (plot A), the total number of curling up episodes 
(plot B), the total number of burrowing episodes (plot C), the total number of 
backward walking episodes (plot D), the total number of rearing episodes (plot E) 
and the total number of defecatory episodes (plot F) occurring during the 
Habituation, Pretreatment and/or Test periods。Significant differences between the 
respective treatment groups are indicated as *P<0.05 or **P<0.01 (Kruskal-Wallis test 
followed by a Dunn's multiple comparison test). 
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3�.2 The Effect of Domperidone on Emesis and Locomotor Activity Changes 
Induced by Apomorphine in the Ferret 
The ferrets were highly active during the 30 min Habituation period: distance 
travelled was 5995.8±402.0 cm (pooled data, n二24) with an average velocity of 
3.3±0.2 cm/s (pooled data, n二24). Analysis of the raw data revealed that 
apomorphine (0.25 mg/kg, s.c.), alone or in combination with domperidone (1 
mg/kg, i.p.), was able to increase the total distance travelled and the velocity of 
movement of animals during the Test period (PO.Ol，Figure 3.4, C & D). In 
addition, apomorphine induced 39.7土7.5 retches + vomits (PO.OOl: Figure 3.4, B) 
following a latency of 2.0±0.4 min (PO.Ol: Figure 3.4, A). Domperidone (1 mg/kg, 
I.p.) significantly reduced the apomorphine-induced emesis (reduction was 79 %； 丨 
PO.OOl: Figure 3.4, B ) �with 4 out of 6 animals totally protected from emesis. 
However, this prevention occurred without affecting the latency to the first retch 
and/or vomit (P>0.05: Figure 3.4, A). 
The spontaneous locomotor activity data of the animals was also normalized to the 
~ respective activity of each animal recorded during the Habituation and Pretreatment 
periods. Using this approach, it was evident that domperidone was inactive as single 
treatment to modify either the distance travelled or the average velocity of the 
animals during the 30 min Pretreatment period (P>0.05: Figure 3.5, Al and A2). 
However, significant differences in spontaneous locomotor activity could be detected 
between the treatment groups when the Test data (collected for an additional 60 min) 
was normalized to the Habituation data (P<0.05: Figure 3.5，B1 and B2). The 
differences mainly related to the action of apomorphine, alone or in combination 
with domperidone: animals receiving apomorphine with vehicle or domperidone 
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were more active during the Test period traveling approximately 2000-6500 % 
further (P<0.05-P<0.001: Figure 3.5, Bl), with 130-300 % increases in the velocity 
of movement, than animals treated with vehicles or domperidone alone (P<0.05-
PO.OOl: Figure 3.5, B2), In addition，domperidone, in combination with 
apomorphine, prevented the increase in distance travelled and the velocity of 
movement induced by apomorphine alone by 54 % and 83 % respectively (P<0。05: 
Figure 3.5，Bl and B2). 
A similar trend in spontaneous locomotor activity was recorded when the Test data 
was normalized to the Pretreatment data. Apomorphine alone, increased the distance 
travelled by 300-600 % (P<0.05: Figure 3.5, CI) and the velocity of movement by 
650-2000w% (P<0.05: Figure 3.5, C2). However, domperidone, in combination with 
apomorphine, failed to modify changes induced by apomorphine alone (P>0.05: 
Figure 3.5，CI and C2). 
The ferrets also exhibited other spontaneous behaviour during the experiments. 
Thus, during the Habituation period, there were 8.5±1.4 (n=24) episodes of lip 
licking, 2.5±1.5 (n=24) episodes of burrowing, 14.1±1.6 (n=24) episodes of rearing, 
1.710.3 (n=24) curling up episodes, 1.4±0.3 (n=24) episodes of backward walking 
and 0.1±0.1 (n=24) episodes of defecation (Figure 3.6, A-F). There was some intra-
treatment group variability in the frequency of burrowing (P<0.05, Figure 3.6, C), 
but it was not possible to normalize the data sets because some animals had zero 
behavioural scores during this period. Analysis of data during the Pretreatment and 
Test times revealed that these spontaneous behaviours were not -altered by the drug 
treatments (P〉0.05: Figure 3.6, A-F). 
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Figure 3.4 The effect of domperidone on emesis and locomotor activity changes 
induced by apomorphine in the ferret. Domperidone (D: 1 mg/kg, i.p.) or vehicle (V: 
DMS〇，0.5 ml/kg, i.p.) was administered after a 30 min habituation period 
(Habituation period) and animals were observed for a further 30 min (Pretreatment 
period). Apomorphine (Apo: 0.25 mg/kg) or vehicle (V: 0.01 % sodium 
metabisulphite, 0.5 ml/kg) was then administered subcutaneously and animals were 
observed for another 60 min period (Test period). Results represent the 
mean士s.e.mean of the total number of emetic episodes (plot B), the total distance 
travelled (plot C) and velocity of movement (plot D) occurring during the 
Habituation, Pretreatment and/or Test periods. Individual latencies to the first 
episode of retching and/or vomiting are shown as filled circles (plot A: horizontal 
lines on the latency plot represent the mean latencies of the respective treatment 
groups). The number of animals retching and/or vomiting out of the number of 
animals tested (RV/T) is also shown. For the latency data (plot A), significant 
differences relative to the V + V treated animals are indicated as **P<0.01，significant 
differences relative to the V+Apo treated animals are indicated as 卞tp<0.01 
(Kruskal-Wallis test followed by aHDunn's multiple comparison test). For the emetic 
episodes data (plot B), significant differences relative to the V + V treated animals are 
indicated as ***P<0.001; significant differences relative to the V + A p o treated animals 
are indicated as 卞卞卞P<0.001 (one-way A N O V A followed by Fisher's P L S D test). For 
the spontaneous locomotor activity data (plots C and D), significant differences 
relative to the respective treatment groups are indicated as "P<0.01 (one-way 
‘ A N O V A followed by Fisher's PLSD test). 
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Figure 3.5 The effect of domperidone and/or apomorphine or respective vehicles on 
spontaneous locomotor activity as normalized to the basal activity (plots Al, A2 and 
Bl, B2) or normalized to the activity of the ferret during the Pretreatment period 
(plots CI and C2). Domperidone, (D: 1 mg/kg, i.p.) or vehicle (V: D M S O , 0.5 
ml/kg, i.p.) was administered after a 30 min Habituation period (i.e. to define the 
basal activity of the animals) and animals were observed for a further 30 min (i.e. 
representing the activity of the animals during the Pretreatment period). 
Apomorphine (Apo: 0.25 mg/kg) or vehicle (V: 0.01 % sodium metabisulphite, 0.5 
ml/kg) was then administered subcutaneously and animals were observed for another 
60 min period (i.e. representing the activity of the animals during the Test period). 
Results represent the mean士s.e.mean of 6 determinaMons. Significant differences 
between the respective treatment groups are indicated as *P<0.05, or ***P<0.001 




























































































































































































































































































































































































































































































































































































































































Figure 3.6 The effect of domperidone and/or apomorphine on the general behaviour 
of the ferret. Domperidone (D: 1 mg/kg, i.p) or vehicle (V: D M S O , 0.5 ml/kg, i.p.) 
was administered after a 30 min habituation period (Habituation period) and animals 
were observed for a further 30 min (Pretreatment period). Apomorphine (Apo: 0.25 
mg/kg) or vehicle (V: 0.01 % sodium metabisulphite, 0.5 ml/kg) was then 
administered subcutaneousiy and animals were observed for another 60 min period 
(Test period). Results represent the mean士s.e.mean of the total number of lip licking 
episodes (plot A), the total number of curling up episodes (plot B), the total number 
of burrowing episodes (plot C), the total number of backward walking episodes (plot 
D), the total number of rearing episodes (plot E) and the total number of defecatory 
episodes (plot F) occurring during the Habituation, Pretreatment and/or Test periods. 
Significant differences between the respective treatment groups are indicated as 
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3.L3 The Effect of CP-99,994 on Emesis and Locomotor Activity Changes 
Induced by Apomorphine in the Ferret 
The ferrets were highly active during the 30 min Habituation period: distance 
travelled was 5924.5±540.9 cm (pooled data, n=24) with an average velocity of 
3.3±0.3 cm/s (pooled data, n=24). Analysis of the raw data revealed that CP-99,994 
10 mg/kg, i.p.) and apomorphine (0.25 mg/kg, s..c.), or their combination, were 
inactive to affect total distance travelled (Figure 3.7, C) or the velocity of movement 
(Figure 3.7, D) of animals during the subsequent Pretreatment and Test times 
(P>0.05). However, apomorphine induced 42.8±6.2 retches + vomits (P<0.001: 
Figure 3.7, B) following a latency of 2.9±0.8 min (PO.OOl: Figure 3.7, A). CP-
99,994 (10 mg/kg, i.p.) prevented apomorphine-induced emesis in all animals 
(P<0.001: Figure 3.7, B). 
The spontaneous locomotor activity data of the animals was also normalized to the 
respective activity of each animal recorded during the Habituation and Pretreatment 
periods. Using this approach, CP-99,994 or vehicle, as single treatments, decreased 
the distance travelled and the average velocity of the animals during the 30 min 
Pretreatment period in some treatment groups (P<0.05: Figure 3.8，Al and Al). 
Apomorphine, but not in combination with CP-99,994, increased the total distance 
travelled and velocity of movement when the 30 min Test data was normalized to the 
Pretreatment data (P<0.05: Figure 3.8, CI and C2), but not to the Habituation data 
(P>0.05, Figure 3.8，B1 and B2). 
The ferrets also exhibited other spontaneous behaviour during the experiments. 
Thus, during the Habituation period, there were 7.7±1.8 (n=24) episodes of lip 
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licking, 0.5±0.3 (n二24) episodes of burrowing, 21.9±3.4 (n二24) episodes of rearing, 
1.1±0.3 (n=24) curling up episodes, L9±1.2 (n=24) episodes of backward walking 
and 0.2±0.1 (n=24) episodes of defecation (Figure 3.9，A-F). Analysis of data during 
the Test time revealed that CP-99,994, in combination with apomorphine, reduced 
significantly the number of episodes of lip licking (reduction was 91.7 %； PO.Ol: 
Figure 3.9，A) and the number of curling up episodes (reduction was 88.9 %; P<0.05: 
Figure 3.9, B) when compared to vehicle-treated animals. 
r . 
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Figure 3.7 The effect of CP-99,994 on emesis and locomotor activity changes 
induced by apomorphine in the ferret. CP-99,994 (CP: 10 mg/kg, i.p.) or vehicle (V: 
distilled water, 0.5 ml/kg, i.p.) was administered after a 30 min habituation period 
(Habituation period) and animals were observed for a further 30 min (Pretreatment 
period). Apomorphine (Apo: 0.25 mg/kg) or vehicle (V: 0.01 % sodium 
metabisulphite, 0.5 ml/kg) was then administered siibcutaneously and animals were 
observed for another 60 min period (Test period). Results represent the 
mean士s.e.mean of the total number of emetic episodes (plot B)，the total distance 
travelled (plot C) and velocity of movement (plot D) occurring during the 
Habituation, Pretreatment and/or Test periods. Individual latencies to the first 
episode of retching and/or vomiting are shown as filled circles (plot A: horizontal 
lines on the latency plot represent the mean latencies of the respective treatment 
groups). The number of animals retching and/or vomiting out of the number of 
animals tested (RV/T) is also shown. For the latency data (plot A), significant 
differences relative to the V + V treated animals are indicated as ***P<0.001, 
significant differences relative to the V+Apo treated animals are indicated as 
卞卞卞PO.OOl (Kruskal-W-allis test followed by a Dunn's multiple comparison test). For 
the emetic episodes data (plot B), significant differences relative to the V + V treated 
animals are indicated as ***P<0.001; significant differences relative to the V + A p o 
treated animals are indicated as 卞卞PO.OOl (one-way A N O V A followed by Fisher's 
P L S D test). There were no significant differences in the locomotor activity measures 
(plots C and D ) between the respective treatment groups (P〉0.05，one-way 
A N O V A ) . 
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Figure 3.8 The effect of CP-99,994 and/or apomorphine or respective vehicles on 
spontaneous locomotor activity as normalized to the basal activity (plots Al, A 2 and 
Bl, B2) or normalized to the activity of the ferret during the Pretreatment period 
(plots CI and C2). CP-99,994, (CP: 10 mg/kg, i.p.) or vehicle (V: distilled water, 0.5 
ml/kg, i.p.) was administered after a 30 min Habituation period (i.e. to define the 
basal activity of the animals) and animals were observed for a further 30 min (i.e. 
representing the activity of the animals during the Pretreatment period). 
Apomorphine (Apo: 0.25 mg/kg) or vehicle (V: 0.01 % sodium metabisulphite, 0.5 
ml/kg) was then administered subcutaneously and animals were observed for another 
60 min period (i.e. representing the activity of the animals during the Test period). 
Results represent the mean士s.e.mean of 6^determinations. Significant differences 
1 * 
between the respective treatment groups are indicated as P<0.05 (one-way A N O V A 

































































































































































































































































































































































































































































































Figure 3.9 The effect of CP-99,994 and/or apomorphine on the general behaviour of 
the ferret. CP-99,994 (CP: 10 mg/kg, i.p) or vehicle (V: distilled water, 0.5 ml/kg, 
i.p.) was administered after a 30 min habituation period (Habituation period) and 
animals were observed for a further 30 min (Pretreatment period). Apomorphine 
(Apo: 0.25 mg/kg) or vehicle (V: 0.01 % sodium metabisulphite, 0.5 ml/kg) was then 
administered subcutaneousiy and animals were observed for another 60 min period 
(Test period). Results represent the mean土s.e.mean of the total number of lip licking 
episodes (plot A), the total number of curling up episodes (plot B), the total number 
of burrowing episodes (plot C), the total number of backward walking episodes (plot 
D), the total number of rearing episodes (plot E) and the total number of defecatory 
episodes (plot F) occurring during the Habituation, Pretreatment and/or Test periods. 
Significant differences between the respective treatment groups are indicated as 
*P<0.05 or "PO.Ol (Kruskal-Wallis test followed by a Dunn's multiple comparison 
test). 
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又 1.4 c-fos Expression Studies in Ferret Brainstems 
3,L4.1 Cisplatin-treated Ferrets 
A number of previous studies have clearly demonstrated c-fos expression in the ferret 
brainstem following treatment with cisplatin and other emetogens (e.g. loperamide) 
(see Section 1.4.2.5) (Reynolds et al., 1991; Zaman et al, 2000). It was considered 
appropriate, therefore, to attempt to replicate the previous findings (as a method of 
validating the immunohistochemical techniques) before progressing to studies on the 
forebrain tissues. A summary of the findings of the present studies is detailed below. 
Essentially, the methodology used to prepare the brain sections for staining was 
consistent throughout the studies. However, the source of the antibodies used in the 
final step to probe the Fos protein was analyzed several times (due to factors outside 
the control of the planned studies) and this proved to be unsatisfactory. Originally, 
the studies were conducted with Sheep polyclonal antibody to Fos oncoprotein (OA-
11-824A) from Sigma-Aldrich (Australia), but this antibody appeared inactive (over 
several concentration ranges) on the ferret tissues. Thus，although the sections were 
stained brown, no c-/os positive staining localized to nuclei was observed in the area 
postrema, nucleus tractus solitarius or dorsal motor vagal nuclei of 6 cisplatin-treated 
animals (i.e. from animals that retched and vomited: Latency 99.4±4.8 min, total 
episodes 39.8±17.1, see section 3.1.1). Similarly, no c-/os staining was observed in 
the respective control saline-treated animals (n=2). Representative sections of these 
brainstem sections (vehicle-treated and cisplatin-treated animals) are shown in Figure 
3.10. 
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Sigma-Aldrich was alerted (via personal correspondence) to the problem of negative 
staining with the antibodies but the company unexpectedly discontinued the product. 
This was unfortunate given the time (8 months) already invested in the studies and 
that Sigma-Aldrich antibodies are the most commonly used, with the conditions of 
the reaction being thoroughly described (Boissonade et al, 1996; Boissonade et al, 
1994; Chattipakom et al., 1999; Zaman et al, 2000). It was therefore necessary to 
purchase and test alternative commercially available c-fos antibodies for the studies. 
Each of the alternative antibodies was evaluated on ferret tissues from animals that 
had a positive emetic response to cisplatin (Latency 99.4±4.8 min, total episodes 
39.8±17.1, see section 3.1.1) and included the following: (1) Goat polyclonal 
：厂 antibodies to c-fos oncoprotein (SC-52-G), Santa Cruz Biotechnology Inc., U.S.A.; 
. (2) Mouse anti-c如 oncoprotein monoclonal antibodies (NCL-FOS), Novocastra 
Laboratories Ltd., U.K.; (3) Rabbit polyclonal antibodies to c-fos oncoprotein (SC-
52), Santa Cruz Biotechnology Inc., U.S.A.; (4) Mouse anti-c如 oncoprotein 
monoclonal antibodies (MAB-1283), Chemicon International, U.S.A.; (5) Rabbit c-
fos polyclonal antibodies (lyophilized) (PC05L-100UG), Oncogene Research 
Products, U.S.A.; (6) Sheep polyclonal antibodies to Q-fos oncoprotein (CBL-400), 一 
Cymbus Biotechnology Ltd., U.K. 
Again, the use of the antibodies characteristically resulted in a light brown staining 
of the ferret tissues. Unfortunately, however, none of the antibodies tested identified 
localized dense c-fos staining in any of the ferret brainstem sections that were 
processed (see Table 3.1 for a summary and Figure 3.11 for representative sections). 
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Figure 3.10 Photographs of the brainstems of (a) vehicle-treated and (b) cisplatin-
treated ferrets, probed against the antibody: Sheep polyclonal antibody to Fos 
oncoprotein, Sigma-Aldrich, Australia. The dilution ratio used was 1:100. The 
thickness of both sections was 30 [am. The images were captured under lOx bright-
field objective. Note that no c-fos positive cells were observed in the area postrema 
(AP), nucleus tractus solitarius (NTS) and the dorsal motor vagal nuclei (DMVN). 
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Figure 3.11 Photographs of the brainstems of cisplatin-treated ferrets, probed 
against the following antibodies: (a) Goat polyclonal antibodies to c-fos oncoprotein 
(SC-52-G), Santa Cruz Biotechnology Inc., U.S.A.; (b) Mouse anti-c如 oncoprotein 
monoclonal antibodies (NCL-FOS), Novocastra Laboratories Ltd., U.K.; (c) Rabbit 
polyclonal antibodies to z-fos oncoprotein (SC-52), Santa Cruz Biotechnology Inc., 
U.S.A.; (d) Mouse anti-o/os oncoprotein monoclonal antibodies ( M A B 1283), 
Chemicon International, U.S.A.; (e) Rabbit o-fos polyclonal antibodies (lyophilized) 
(PC05L-100UG), Oncogene Research Products, U.S.A.; (f) Sheep polyclonal 
antibodies to c-fos oncoprotein (CBL-400), Cymbus Biotechnology Ltd., U.K.. The 
dilution ratios used, as suggested by the respective suppliers, were: (a) 1:500; (b) 
1:100; (c) 1:500; (d) 1:50; (e) l:100『（f) 1:200. The thickness of the sections are 30 
jim. The images were captured under lOx bright-field objectives. Note that no c-fos 
positive cells were observed in the area postrema (AP), nucleus tractus solitarius 
(NTS) and the dorsal motor vagal nuclei (DMVN). 
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Table 3.1 Summary of the o-fos staining of ferret brainstem sections with various 
antibodies. 
Antibody Supplier Dilution c-fos staining  
ratio AP NTS DMNV 
Sheep polyclonal antibodies Sigma-Aldrich, 1:100/1:500 Negative Negative Negative 
to Fos oncoprotein (OA-11- Australia 
824A) 
Goat polyclonal antibodies Santa Cruz 1:100/1:500 Negative Negative Negative 
to Q-fos oncoprotein (SC-52- Biotechnology, U.S.A. 
G ) 
Mouse anti-c-/05 Novocastra 1:100 Negative Negative Negative 
oncoprotein monoclonal Laboratories Ltd., 
antibodies (NCL-FOS) U.K. 
Rabbit polyclonal antibodies Santa Cruz 1:100/1:500 Negative Negative Negative 
to of OS oncoprotein (SC-52) Biotechnology, U.S.A. 
Mouse anti-c-/ay Chemicon 1:50 Negative Negative Negative 
oncoprotein monoclonal International, U.S.A. 
antibodies ( M A B 1283) 
Rabbit c-fos polyclonal Oncogene Research 1:100/1:500 Negative Negative Negative 
antibodies (lyophilized) Products, U.S.A. 
(PC05L-100UG) 
Sheep polyclonal antibodies Cymbus 1:200 Negative Negative Negative 
to z-fos oncoprotein (CBL- Biotechnology Ltd., 
400) ^  
Note that the above results represent a summary of at least 20 brainstem sections per each 
commercial antibody, taken with a distance approximately 14 mm caudal to the anterior end of the 
"Block 4" (see section 2.4.3), with the area postrema (AP), nucleus tractus solitarius (NTS) and 
do蘭I motor vagal nuclei (DMNV) included. Four cisplatin-treated animals were used in the studies 
and they exhibited 59.3±20.5 retches and/or vomits (Latency to first retch/vomit was 96.7±6.1 min) 
prior to being anesthetized. 
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3,1.4.2 Positive Control Slides 
The absence of c-fos positive staining in the brainstem sections, after processing with 
several commercial sources of c-fos antibodies, under different conditions, was a 
serious concern. At this stage it was considered necessary, therefore, to purchase 
some commercially available c-fos positive control tissues to validate the 
immunohistochemical procedures used in the present investigations. Specifically, 
formalin-fixed and paraffin embedded human colon carcinoma tissues were 
purchased (Oncogene Research Products, U.S.A.) and processed with all the 
antibodies to c-fos that were available. Brown staining of the tissues was observed 
using all the antibodies. However, in contrast to the ferret tissues, it was possible to 
identify positive c-fos staining, which were localized to the nuclpi, (n=2, Figure 3.12) 
using c-fos antibodies: (1) Goat polyclonal antibodies to c-fos oncoprotein (SC-52-G), 
Santa Cruz Biotechnology Inc., U.S.A.; (2) Mouse anti-c/oy oncoprotein 
monoclonal antibodies (NCL-FOS), Novocastra Laboratories Ltd, U.K.; (3) Rabbit 
polyclonal antibodies to o-fos oncoprotein (SC-52), Santa Cruz Biotechnology Inc., 
U.S.A.; (4) Mouse anti-c-/o^  oncoprotein monoclonal antibodies ( M A B 1283), 
Chemicon International, U.S.A. Conversely, no c~fos positive cells were identified 
by: (1) Rabbit c-fos polyclonal antibodies (lyophilized) (PC05L-100UG), Oncogene 
Research Products, U.S.A. or with (2) Sheep polyclonal antibodies to c-fos 
oncoprotein (CBL-400), Cymbus Biotechnology Ltd., U.K. A summary of findings 
is presented in Table 3.2. 
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Figure 3.12 Fos positive slides (human colon carcinoma) probed against the 
antibodies: (a) Goat polyclonal antibodies to o-fos oncoprotein (SC-52-G), Santa 
Cruz Biotechnology Inc., U.S.A.; (b) Mouse oxvli-c-fos oncoprotein monoclonal 
antibodies (NCL-FOS), Novocastra Laboratories Ltd., U.K.; (c) Rabbit polyclonal 
antibodies to c-fos oncoprotein (SC-52), Santa Cruz Biotechnology Inc., U.S.A.; (d) 
Mouse anti-c如 oncoprotein monoclonal antibodies ( M A B 1283), Chemicon 
International, U.S.A.; (e) Rabbit c-fos polyclonal antibodies (lyophilized) (PC05L-
lOOUG), Oncogene Research Products, U.S.A.; (f) Sheep polyclonal antibodies to c-
fos oncoprotein (CBL-400), Cymbus Biotechnology Ltd., U.K. The dilution ratios 
used, as suggested by the respective suppliers, are: (a) 1:500; (b) 1:100; (c) 1:100; (d) 
- 1:50; (e) 1:100; (f) 1:200. The thickness of the sections were 8 jim。The images in 
• the left and right columns were captured under lOx and 20x bright-field objectives 
respectively. Fos positive cells are highlighted by arrows. 
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Table 3.2 Summary of staining of the human colon carcinoma tissues by various 
antibodies to c-fos, 
Antibody Supplier Dilution ratio staining 
Sheep polyclonal Sigma-Aldrich, Australia Unable to verify since Unable to verify since 
antibodies to Fos discontinuation of discontinuation of 
oncoprotein (OA-11- production production 
824A) 
Goat polyclonal Santa Cruz Biotechnology, 1:500 Positive 
antibodies to c-fos U.S.A. 
oncoprotein (SC-52-G) 
Mouse anti-c-/ay Novocastra Laboratories 1:100 positive 
oncoprotein monoclonal Ltd., U.K. 
antibodies (NCL-FOS) 
Rabbit polyclonal Santa Cruz Biotechnology, 1:100 Positive 
antibodies to c-fos U.S.A. 
oncoprotein (SC-52) 
Mouse anti-c-/o5 Chemicon International, 1:50 Positive 
oncoprotein monoclonal U.S.A. 
antibodies ( M A B 1283) 
Rabbit c-fos polyclonal Oncogene Research 1:100 Negative 
antibodies (lyophilized) Products, U.S.A. 
(PC05L-100UG) 
Sheep polyclonal Cymbus Biotechnology 1:200 Negative 
antibodies to o-fos Ltd., U.K. 
oncoprotein (CBL-400)  
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3.2 Suncus murinus 
3.2,1 The Emetic Potential of Nicotine and its Effects on the Spontaneous 
Locomotor Activity of Suncus murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 10913.6±993.9 cm (pooled data, n=18) with an average velocity of 
6.1±0.6 cm/s (pooled data, n=18). N o animal exhibited retching and/or vomiting 
during the Habituation period (data not shown). 
Nicotine at 5 mg/kg, s.c. was emetic in 6 out of 6 animals tested and induced 
I 
20.3±2.1 episodes (PO.OOl: Figure 3.13, B) following a latency of 6.1士0.8 min 
(PO.OOl: Figure 3.13, A). There was a trend for nicotine to reduce dose-
dependently the distance travelled and the average velocity of Suncus murinus during 
the Test period, but statistical significance was only observed at nicotine 5 mg/kg; 
this dose reduced the total distance travelled (by approximately 84 % ) and average 
velocity of animals (by approximately 75 % ) (analysis of raw data; PO.Ol: Figure 
3.13, C and D). 
The spontaneous locomotor activity data of the animals receiving nicotine or vehicle 
was also normalized to the respective activity of each animal recorded during the 
Habituation period. Using this approach, it was evident that, although there was a 
trend for nicotine to dose-dependently reduce the total distance travelled and the 
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velocity of movement of animals, significant differences were only observed at 
nicotine at 5 mg/kg, s.c. (PO.Ol: Figure 3.14, A and B). 
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Figure 3.13 The emetic potential of nicotine and its effect on the spontaneous 
locomotor activity of Suncus murinus. The administration of nicotine (1.25-5 mg/kg, 
s.c.) or vehicle (distilled water, 2 ml/kg, s.c.) was performed after a 30 min 
habituation period (Habituation period) and animals were then observed for a further 
30 min (Test period). Results represent the mean士s.e.mean of the total number of 
emetic episodes (plot B), the total distance travelled (plot C) and velocity of 
movement (plot D) occurring during the Habituation and/or Test periods. Individual 
latencies to the first episode of retching and/or vomiting are shown as filled circles 
(plot A: horizontal lines on the latency plot represent the mean latencies of the 
respective treatment groups). The number of animals retching and/or vomiting out of 
the number of animals tested (RV/T) is also shown. For the latency data (plot A), 
significant differences relative to the vehicle-treated animals are indicated as 
***P<0.001 (Kruskal-Wallis test followed by a Dunn's multiple comparison test). For 
the emetic episodes data (plot B), significant differences relative to the vehicle-
treated animals are indicated as ***P<0.001 (one-way A N O V A followed by Fisher's 
PLSD test). For the spontaneous locomotor activity data (plots C and D), significant 
differences relative to the respective treatment groups are indicated as P<0.01 (one-
way A N O V A followed by Fisher's PLSD test). 
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Figure 3.14 The effect of nicotine on spontaneous locomotor activity normalized to 
the basal activity (see Figure 3.13) of Suncus murinus. Basal activity (plot A: 
distance travelled and plot B: velocity) was defined during a 30 min Habituation 
period. Nicotine (1.25-5 mg/kg, s.c.) or vehicle (distilled water, 2 ml/kg, s.c.) was 
administered at the end of the Habituation period and spontaneous locomotor activity 
was assessed for a further 30 min (equivalent to the Test period in Figure 3.13). 
Results represent the mean土s.e.mean of 6 determinations. Significant differences 
relative to the vehicle-treated animals are indicated as **P<0.01 (one-way A N O V A 
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J.2.2 The Effect of CP-99,994 on Emesis and Locomotor Activity Changes 
Induced by Nicotine in Suncus murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 8140.2土736.6 cm (pooled data, n=24) with an average velocity of 
4.5±0.4 cm/s (pooled data, n=24). CP-99,994 (3-10 mg/kg, i.p.) failed to affect the 
total distance travelled or the velocity of movement of animals during the subsequent 
Pretreatment time (analysis of raw and normalized data; P>0.05: Figure 3.15, C and 
D; Figure 3.16, Al and A2). Nicotine (5 mg/kg, s.c.) induced 16.3±1.9 episodes of 
retching and/or vomiting (PO.OOl; Figure 3.15, B) following a latency of 4.8±0.8 
min (PO.Ol: Figure 3.15, A) but failed to modify significantly the distance travelled 
of the velocity of movement recorded during the subsequent 30 min Test time 
(analysis of raw and normalized data; P>0.05: Figure 3.15, C and D; Figure 3.16, Bl, 
B2, CI and C2). CP-99,994 dose-dependently reduced nicotine-induced emesis 
(maximum reduction was 55.4 % at 10 mg/kg, s.c.; PO.OOl: Figure 3.15, B) without 
affecting the latency to first emetic episode (P>0.05: Figure 3.15, A ) or the distance 
travelled or the velocity of the animals (analysis of raw and normalized dat^ P>0.05: 
Figure 3.15, C and D; Figure 3.16, Bl, B2, CI and C2) during the Test period. 
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Figure 3.15 The effect of CP-99,994 on emesis and locomotor activity changes 
induced by nicotine in Suncus murinus. CP-99,994 (CP: 3-10 mg/kg, i.p.) or vehicle 
(V: distilled water, 2 ml/kg, i.p.) was administered after a 30 min habituation period 
(Habituation period) and animals were observed for a further 30 min (Pretreatment 
period). Nicotine (N: 5 mg/kg) or vehicle (V: distilled water, 2 ml/kg) was then 
administered subcutaneously and animals were observed for another 30 min period 
(Test period). Results represent the mean土s.e.mean of the total number of emetic 
episodes (plot B), the total distance travelled (plot C) and velocity of movement (plot 
D) occurring during the Habituation, Pretreatment and/or Test periods. Individual 
latencies to the first episode of retching and/or vomiting are shown as filled circles 
(plot A: horizontal lines on the latency plot represent the mean latencies of the 
respective treatment groups). The number of animals retching and/or vomiting out of 
the number of animals tested (RV/T) is also shown。For the latency data (plot A), 
significant differences relative to the V + V treated animals are indicated as *P<0.05 or 
"PO.Ol (Kruskal-Wallis test followed by a Dunn's multiple comparison test). For 
the emetic episodes data (plot B), significant differences relative to V + V treated 
animals are indicated as '**P<0.001; significant differences relative to V + N treated 
animals are indicated as 卞P<0.05 or 卞卞卞PO.OOl (one-way A N O V A followed by 
Fisher's P L S D test). There were no significant differences in the locomotor activity 
measures (plots C and D) between the respective treatment groups (P>0.05, one-way 
A N O V A ) . 
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Figure 3.16 The effect of CP-99,994 and/or nicotine or respective vehicles on 
spontaneous locomotor activity as normalized to the basal activity (plots Al, A2 and 
Bl, B2) or normalized to the activity of Suncus murinus during the Pretreatment 
period (plots CI and C2). CP-99,994 (CP: 3-10 mg/kg, i.p.) or vehicle (V: distilled 
water, 2 ml/kg, i.p.) was administered after a 30 min Habituation period (i.e. to 
define the basal activity of the animals) and animals were observed for a further 30 
min (i.e. representing the activity of the animals during the Pretreatment period). 
Nicotine (N: 5 mg/kg) or vehicle (V: distilled water, 2 ml/kg) was then administered 
subcutaneousiy and animals were observed for another 30 min period (i.e. 
representing the activity of the animals during the Test period). Results represent the 
mean士s.e.mean of 6 dete|minations. There were no significant differences between 
i i 
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3.2.3 The Emetic Potential of Copper Sulphate and its Effects on the Spontaneous 
Locomotor Activity of Suncus murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 7836.2±654.3 cm (pooled data, n二27) with an average velocity of 
4.4±0.4 cm/s (pooled data, n二27). N o animal exhibited retching and/or vomiting 
during the Habituation period (data not shown). 
The administration of copper sulphate at 10 mg/kg, intragastric failed to induce 
emesis (P>0.05: Figure 3.17, B), or affect the total distance travelled or velocity of 
movement of Suncus murinus during the Test time (analysis of raw data; P>0.05: 
Figure 3.17, C and D). Copper sulphate at 120 mg/kg, intragastric induced emesis in 
9 out of 9 animals tested and with 14.7±0.9 episodes (P<0.001: Figure 3.17, B) 
following a latency of 3.5土0.6 min (PO.OOl: Figure 3.17, A), but failed to affect the 
distance travelled or the velocity of movement of Suncus murinus in the 30 min Test 
period (analysis of raw data; P>0.05: Figure 3.17, C and D). 
The spontaneous locomotor activity data of the animals receiving copper sulphate or 
vehicle was subsequently normalized to the respective activity of each animal 
recorded during the Habituation period. Using this approach, it was still evident that 
copper sulphate had no action on the distance travelled or velocity of movement of 
Suncus murinus (analysis of normalized data; P>0.05: Figure 3.18, A and B). 
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Figure 3.17 The emetic potential of copper sulphate and its effect on the 
spontaneous locomotor activity of Suncus murinus. The administration of copper 
sulphate (10-120 mg/kg, intragastric) or vehicle (distilled water, 2 ml/kg, 
intragastric) was performed after a 30 min habituation period (Habituation period) 
and animals were then observed for a further 30 min (Test period). Results represent 
the mean士s.e.mean of the total number of emetic episodes (plot B), the total distance 
travelled (plot C) and velocity of movement (plot D) occurring during the 
Habituation and/or Test periods. Individual latencies to the first episode of retching 
and/or vomiting are shown as filled circles (plot A: horizontal lines on the latency 
plot represent the mean latencies of the respective treatment groups). The number of 
animals retching and/or vomiting out of the number of animals tested (RV/T) is also 
shown. For the latency data (plot A), significant differences relative to the vehicle-
treated animals are indicated as ***P<0.001 (Kruskal-Wallis test followed by a 
Dunn's multiple comparison test). For the emetic episodes data (plot B), significant 
** t 
differences relative to the vehicle-treated animals are indicated as P<0.001 (one-
way A N O V A followed by Fisher's P L S D test). There were no significant 
differences in the locomotor activity measures (plots C and D) between the 
respective treatment groups (P〉0.05, one-way A N O V A ) . 
(A) (B) 
RV/T 0/9 0/9 9/9 
10n 20-| 
8 - *资关 ？ ： 15- — I -
• : • "a-
• • • i 
• • • 
( J — , , 
0 10 120 0 10 120 
C u S 0 4(mg/kg) C u S 0 4(mg/kg) 
10000, (C) T 6, (D) 
•s m T 5- 丁 I 
^ 7500- T r n ：^ T P I 「 — 
= ‘‘‘：'‘ / ‘ ？ ‘ f ： 4 - ‘ ？ 
g , ； ；- 0 厂 ：：/-/ 緩 
2 5000- 二 丁 ； > > 3- m 
‘, , ‘ _ _ 0 ① -p 力‘‘•• , “ C\  
呂 ： ^ ： • 2- ；；： T 7K II 
I 2500- ； ；： • ”，• > ;； • • :々,::：T 岂 J _ J _ l i :L-L.iJ_iJL 
0 10 120 0 10 120 
C u S O 4 (mg/kg) C u S O 4 (mg/kg) 
I- " 1 Habituation Period ！ I Test Period 
96 
Figure 3.18 The effect of copper sulphate on spontaneous locomotor activity 
normalized to the basal activity (see Figure 3.17) of Suncus murinus. Basal activity 
(plot A: distance travelled and plot B: velocity) was defined during a 30 min 
Habituation period. Copper sulphate (10-120 mg/kg, intragastric) or vehicle 
(distilled water, 2 ml/kg, intragastric) was administered at the end of the Habituation 
period and spontaneous locomotor activity was assessed for a further 30 min 
(equivalent to the Test period in Figure 3.17). Results represent the mean士s.e.mean 
of 9 determinations. There were no significant differences relative to the vehicle-

























































































































































Chapter 3 - Results 
3.2.4 The Effect of CP-99,994 on Emesis and Locomotor Activity Changes 
Induced by Copper Sulphate in Suncus murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 6846.2土575.8 cm (pooled data, n=28) with an average velocity of 
3.8±0.3 cm/s (pooled data, n二28). CP-99,994 (3-10 mg/kg, i.p.) failed to affect total 
distance travelled or the velocity of movement of animals during the subsequent 
Pretreatment time (analysis of raw and normalized data; P>0.05: Figure 3.19, C and 
D; Figure 3.20, Al and A2). Copper sulphate (120 mg/kg, intragastric) induced 
13.4±0.9 episodes of retching and/or vomiting (P<0.001; Figure 3.19, B) following a 
latency of 4.9±1.2 min (PO.OOl: Figure 3.19, A), but failed to modify significantly 
the distance travelled of the velocity of movement recorded during the subsequent 30 
min Test time (analysis of raw and normalized data; P〉0。05: Figure 3.19, C and D; 
Figure 3.20，Bl, B2, CI and C2). There was a trend for CP-99,994 to dose-
dependently reduce the copper sulphate-induced emesis but this was only significant 
at 10 mg/kg, i.p. (reduction was 70.2 %; P<0.001: Figure 3.19, B). CP-99,994 failed 
_ to affect the latency to first emetic episode (P>0.05: Figure 3.19, A ) or the distance 
travelled or the velocity of the animals (analysis of raw and normalized data; P>0.05: 
Figure 3.19, C and D; Figure 3.20, Bl, B2, CI and C2) treated with copper sulphate 
and vehicle during the Test period. 
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Figure 3.19 The effect of CP-99,994 on emesis and locomotor activity changes 
induced by copper sulphate in Suncus murinus. CP-99,994 (CP: 3-10 mg/kg, i.p.) or 
vehicle (V: distilled water, 2 ml/kg, i.p.) was administered after a 30 min habituation 
period (Habituation period) and animals were observed for a further 30 min 
(Pretreatment period). Copper sulphate (Cu: 120 mg/kg, intragastric) or vehicle (V: 
distilled water, 2 ml/kg, intragastric) was then administered and animals were 
observed for another 30 min period (Test period). Results represent the 
mean士s.e.mean of the total number of emetic episode (plot B), the total distance 
travelled (plot C) and velocity of movement (plot D) occurring during the 
Habituation, Pretreatment and/or Test periods. Individual latencies to the first 
episode of retching and/or vomiting are shown as filled circles (plot A: horizontal 
I 
lines on the latency plot represent the mean latencies of the respective treatment 
groups). The number of animals retching and/or vomiting out of the number of 
animals tested (RV/T) is also shown. For the latency data (plot A), significant 
differences relative to the V + V treated animals are indicated as **P<0.01 or 
***P<0.001 (Kruskal-Wallis test followed by a Dunn's multiple comparison test). For 
the emetic episodes data (plot B), significant differences relative to V + V treated 
animals are indicated as *P<0.05 or ***P<0.001; significant differences relative to 
V + C u treated animals are indicated as 卞卞PO.OOl (one-way A N O V A followed by 
Fisher's P L S D test). There were no significant differences in the locomotor activity 
measures (plots C and D) between the respective treatment groups (P〉0.05, one-way 
A N O V A ) . 
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Figure 3.20 The effect of CP-99,994 and/or copper sulphate or respective vehicles 
on spontaneous locomotor activity as normalized to the basal activity (plots Al, A2 
and Bl, B2) or normalized to the activity of Suncus murinus during the Pretreatment 
period (plots CI and C2). CP-99,994 (CP: 3-10 mg/kg, i.p.) or vehicle (V: distilled 
water, 2 ml/kg, i.p.) was administered after a 30 min Habituation period (i.e. to 
define the basal activity of the animals) and animals were observed for a further 30 
min (i.e. representing the activity of the animals during the Pretreatment period). 
Copper sulphate (Cu: 120 mg/kg, intragastric) or vehicle (V: distilled water, 2 ml/kg, 
intragastric) was then administered and animals were observed for another 30 min 
period (i.e. representing the activity of the animals during the Test period). Results 
represent the mean士s.e.mean of 7 determinations. There were no significant 














































































































































































































































































































































































































































































Chapter 3 - Results 
又 The Emetic Potential of Cisplatin and its Effects on the Spontaneous 
Locomotor Activity of Suncus murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 10217.811108.1 cm (pooled data, n二24) with an average velocity of 
5.7±0.6 cm/s (pooled data, n=24). However, there was some intra-treatment group 
variabilities (P<0.05-0.01) in the distance travelled and average velocity of animals 
that were scheduled to receive either cisplatin at 10 and 30 mg/kg, s.c. (Figure 3.21, 
C and D). N o animal exhibited retching and/or vomiting during the Habituation 
period (data not shown). 
The administration of cisplatin at 10 mg/kg, i.p. failed to induce emesis (P>0.05: 
, I 
Figure 3.21, B)，or the total distance travelled or the velocity of movement of Suncus 
murinus during the Test time (analysis of raw data; P>0.05: Figure 3.21, C and D). 
Cisplatin at 30 mg/kg, i.p. was emetic in 7 out of 8 animals tested and induced 
15.3±3.5 episodes (PO.OOl: Figure 3.21, B) following a latency of 39.3±2.9 min 
(PO.OOl: Figure 3.21, A), but failed to affect the distance travelled (Figure 3.21，C) 
and the velocity of movement (Figure 3.21, D) of Suncus murinus in the 30 min Test 
period. 
The spontaneous locomotor activity data of the animals receiving cisplatin or vehicle 
was subsequently normalized to the respective activity of each animal recorded 
during the Habituation period. Using this approach, it was still evident that cisplatin 
had no effect on the distance travelled or the velocity of movement of Suncus -
murinus (analysis of normalized data; P>0.05: Figure 3.22, A and B). 
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Figure 3.21 The emetic potential of cisplatin and its effect on the spontaneous 
locomotor activity of Suncus murinus. The administration of cisplatin (10-30 mg/kg, 
i.p.) or vehicle (saline, 10 ml/kg, i.p.) was performed after a 30 min habituation 
period (Habituation period) and animals were observed for a further 240 min (Test 
period). Results represent the mean土s.e.mean of the total number of emetic episodes 
(plot B), the total distance travelled (plot C) and velocity of movement (plot D) 
occurring during the Habituation and/or Test periods. Individual latencies to the first 
episode of retching and/or vomiting are shown as filled circles (plot A: horizontal 
lines on the latency plot represent the mean latencies of the respective treatment 
groups). The number of animals retching and/or vomiting out of the number of 
animals tested (RV/T) is also shown. For the latency data (plot A), significant 
本*伞 
differences relative to the vehicle-treated animals are indicated as P<0.001 
(Kruskal-Wallis test followed by a Dunn's multiple comparison test). For the emetic 
episodes data (plot B), significant differences relative to the vehicle-treated animals 
are indicated as "*P<0.001 (one-way A N O V A followed by Fisher's PLSD test). For 
the spontaneous locomotor activity data (plots C and D), significant differences 
relative to the respective treatment groups are indicated as P<O.-05 or P<0.01 (one-
way A N O V A followed by Fisher's PLSD test). 
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Figure 3.22 The effect of cisplatin on spontaneous locomotor activity normalized to 
the basal activity (see Figure 3.21) of Suncus murinus. Basal activity (plot A: 
distance travelled and plot B: velocity) was defined during a 30 min Habituation 
period. Cisplatin (10-30 mg/kg, i.p.) or vehicle (saline, 10 ml/kg, i.p.) was 
administered at the end of the Habituation period and spontaneous locomotor activity 
was assessed for a further 240 min (equivalent to the Test period in Figure 3.21). 
Results represent the mean土s.e.mean of 8 determinations. There were no significant 

























































































































Chapter 3 - Results 
3.2.(5 The Effect of Ondansetron on Emesis and Locomotor Activity Changes 
Induced by Cisplatin in Suncus murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 10645.0±748.3 cm (pooled data, n=32) with an average velocity of 
5.9±0.4 cm/s (pooled data, n=32). Cisplatin (30 mg/kg, i.p.) induced 14.6土2.7 
episodes of retching and/or vomiting (P<0。001; Figure 3.23, B) following a latency 
of 50.8±4.4 min (PO.OOl: Figure 3.23, A) but failed to modify significantly the 
distance travelled or the velocity of movement recorded during the subsequent 30 
min Test time (analysis of raw and normalized data; P>0.05: Figure 3.23, C and D; 
Figure 3.24, A and B). Ondansetron dose-dependently reduced cisplatin-induced 
emesis (maximum reduction was 98.3 % at 3 mg/kg, s.c.; P<0.001: Figure 3.23, B), 
and also increased the number of animals that were totally protected from emesis 
(maximum protection was 7, out of 8 animals, at 3 mg/kg, s.c.). Ondansetron (1 
mg/kg, s.c.) delayed the latency to the first emetic episode significantly (P<0.001: 
Figure 3.23, A). Ondansetron (1-3 mg/kg, s.c.) had no effect on the distance travelled 
or the velocity of movement of the animals (analysis of raw and normalized data; 
P>0.05: Figure 3.23, C and D; Figure 3.24，A and B) during the Test period. 
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Figure 3.23 The effect of ondansetron on emesis and locomotor activity changes 
induced by cisplatin in Suncus murinus. Ondansetron (ON: 1-3 mg/kg, s.c.) or 
vehicle (V: saline, 2 ml/kg, s.c.) and cisplatin (Pt: 30 mg/kg, i.p.) or vehicle (V: 
saline 10 ml/kg, i.p.), were administered after a 30 min habituation period 
(Habituation period) and animals were observed for a further 240 min (Test period). 
Results represent the mean士s.e.mean of the total number of emetic episodes (plot B), 
the total distance travelled (plot C) and velocity of movement (plot D) occurring 
during the Habituation and/or Test periods. Individual latencies to the first episode of 
retching and/or vomiting are shown as filled circles (plot A: horizontal lines on the 
latency plot represent the mean latencies of the respective treatment groups). The 
number of animals retching and/or vomiting out of the number of animals tested 
(RV/T) is also shown. For the latency data (plot A), significant differences relative 
to the V + V treated animals are indicated as ***P<0.001, significant differences 
relative to the V+Pt treated animals are indicated as 卞卞卞PO.OOl (Kruskal-Wallis test 
followed by a Dunn's multiple comparison test). For the emetic episodes data (plot 
B), significant differences relative to the V + V treated animals are indicated as 
***P<0.001; significant differences relative to V+Pt treated animals are indicated as 
卞卞卞P<0.001 (one-way A N O V A followed by Fisher's P L S D test). There were no 
significant differences in the locomotor activity measures (plots C and D) between 
the respective treatment groups (P>0.05, one-way A N O V A ) . 
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Fiaure 3.24 The effect of ondansetron and/or cisplatin or respective vehicles on to 
spontaneous locomotor activity normalized to the basal activity of Suncus murinus. 
Basal activity (plot A: distance travelled and plot B: velocity) was defined during a 
30 min Habituation period (see Figure 3.23). Drugs or vehicles were administered at 
the end of the Habituation period and spontaneous locomotor activity was assessed 
for a further 240 min (equivalent to the Test period in Figure 3.23). Results 
represent the mean士s.e.mean of 8 determinations. There were no significant 
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Chapter 3 - Results 
7 The Effect of CP-99,994 on Emesis and Locomotor Activity Changes 
Induced by Cisplatin in Suncus murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 7194.5±725.2 cm (pooled data, n二32) with an average velocity of 
4.0±0.4 cm/s (pooled data, n=32). Cisplatin (30 mg/kg, i.p.) induced 14,5±3.4 
episodes of retching and/or vomiting (P<0.001; Figure 3.25, B) following a latency 
of 47.8±.4.9 min (P<0.01: Figure 3.25, A) but failed to modify significantly the 
distance travelled or the velocity of movement recorded during the subsequent 30 
min Test time (analysis of raw data; P>0.05: Figure 3.25, C and D). There was a 
trend of CP-99,994 to dose-dependently reduced the cisplatin-induced emesis during 
the Test period, but the reduction was only significant at 10 mg/kg, s.c. (reduction 
was 40.5 %; P<0.05: Figure 3.25, B). The latency to the first emetic episode was not 
affected by CP-99,994, 3 mg/kg and 10 mg/kg, s.c. (P>0.05: Figure 3.25, A); CP-
99,994 also failed to modify the distance travelled or the velocity of movement of the 
animals (analysis of raw data; P>0.05: Figure 3.25, C and D) during the Test period . 
However, when the spontaneous locomotor activity data of the animals receiving 
cisplatin and/or vehicle was subsequently normalized to the respective activity of 
each animal recorded during the Habituation period, it was evident that cisplatin (30 
mg/kg, i.p.) reduced both the distance travelled and the velocity of movement of 
Suncus murinus (analysis of normalized data; P<0.05-0.01: Figure 3.26, A & B), and 
that these reductions were not prevented by CP-99,994 (3-10 mg/kg, s.c.). 
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Figure 3.25 The effect of CP-99,994 on emesis and locomotor activity changes 
induced by cisplatin in Suncus murinus. CP-99,994 (CP: 3-10 mg/kg, s.c.) or vehicle 
(V: distilled water, 2 ml/kg, s.c.) and cisplatin (Pt: 30 mg/kg, i.p.) or vehicle (V: 
saline 10 ml/kg, i.p.), were administered after a 30 min habituation period 
(Habituation period) and animals were observed for a further 240 min (Test period). 
Results represent the mean士s.e.mean of the total number of emetic episodes (plot B), 
the total distance travelled (plot C) and velocity of movement (plot D) occurring 
during the Habituation and/or Test periods. Individual latencies to the first episode of 
retching and/or vomiting are shown as filled circles (plot A: horizontal lines on the 
latency plot represent the mean latencies of the respective treatment groups). The 
number of animals retching and/or vomiting out of the number of animals tested 
t 
(RV/T) is also shown. For the latency data (plot A), significant differences relative 
to the V + V treated animals are indicated as *P<0.05 or **P<0.01 (Kruskal-Wallis test 
followed by a Dunn's multiple comparison test). For the emesis data (plot B), 
significant differences relative to the V + V treated animals are indicated as P<0.01 
or ***P<0.001; significant differences relative to V+Pt treated animals are indicated 
as 卞P<0.05 (one-way A N O V A followed by Fisher's PLSD test). There were no 
significant differences in the locomotor activity measures (plots C and D) between 
the respective treatment groups (P>0.05, one-way A N O V A ) . 
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Figure 3.26 The effect of CP-99,994 and/or cisplatin or respective vehicles on 
spontaneous locomotor activity normalized to the basal activity of Suncus murinus. 
Basal activity (plot A: distance travelled and plot B: velocity) was defined during a 
30 min Habituation period (see Figure 3.25). Drugs or vehicles were administered at 
the end of the Habituation period and spontaneous locomotor activity was assessed 
for a further 240 min (equivalent to the Test period in Figure 3.25). Results 
represent the mean土s.e.mean of 8 determinations. Significant differences relative to 
the V + V treated animals are indicated as *P<0.05 or **P<0.01 (one-way A N O V A 
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Chapter 3 - Results 
3.2.8 The Effects of Ondansetron and CP-99,994 on Locomotor Activity in Suncus 
murinus 
The animals were highly active during the 30 min Habituation period: distance 
travelled was 8872±644.6 cm (pooled data, n=48) with an average velocity of 
4.9±0.4 cm/s (pooled data, n-48). N o animal exhibited retching and/or vomiting 
during the Habituation period (data not shown). 
Ondansetron (1-3 mg/kg, s.c.) and CP-99,994 (3-10 mg/kg, i.p. and s.c.) did not 
affect the distance travelled or the velocity of movement of Suncus murinus in the 
Test period (analysis of raw and normalized data; P>0.05: Figure 3.27, A1-C2; 
Figure 3.28, A1-C2). 
no 
Figure 3.27 The effect of ondansetron or CP-99,994 on the spontaneous locomotor 
activity of Suncus murinus. Ondansetron (plots Al and A2: 1-3 mg/kg, s.c.) or CP-
99,994 (plots CI and C2: 3-10 mg/kg, s.c.) or vehicle (saline, 2 ml/kg, s.c. or distilled 
water, 2 ml/kg, s.c.) was performed after a 30 min habituation period (Habituation 
period) and animals were then observed for a further 240 min (Test period). In 
another experiment, CP-99,994 (plots Bl and B2: 3-10 mg/kg, i.p.) or vehicle 
(distilled water, 2 ml/kg, i.p.) was performed after a 30 min habituation period 
(Habituation period) but the animals were then observed for a further 30 min (Test 
period). Results represent the mean士s.e.mean of the total distance travelled and 
velocity of movement occurring during the Habituation and/or Test periods. There 
were no significant differences nn the locomotor activity measures (plots C and D) 
between the respective treatment groups (P>0.05, one-way A N O V A ) . 
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Figure 3.28 The effect of ondansetron and CP-99,994 on spontaneous locomotor 
activity normalized to the basal activity (see Figure 3.27) of Suncus murinus. Basal 
activity was defined during a 30 min Habituation period. Ondansetron (plots Al and 
A2: 1-3 mg/kg, s.c.) or CP-99,994 (plots CI and C2: 3-10 mg/kg, s.c.) or vehicle 
(saline, 2 ml/kg, s.c. or distilled water, 2 ml/kg, s.c.) was performed after a 30 min 
habituation period (Habituation period) and animals were then observed for a further 
240 min (Test period). In another experiment, CP-99,994 (plots Bl and B2: 3-10 
mg/kg, i.p.) or vehicle (distilled water, 2 ml/kg, i.p.) was performed after a 30 min 
habituation period (Habituation period) but the animals were then observed for a 
further 30 min (Test period). Results represent the mean士s.e.mean of 4-6 
determinations. There were no significant differences relative to the vehicle treated 
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CHAPTER 4 DISCUSSION 
The primary aim of the present study was to correlate behavioural changes induced 
by emetic drugs with c-fos expression in the forebrain and hindbrain of the ferret. 
The studies were to extend the current knowledge on the organization of the emetic 
reflex that has mainly focused in the role of hindbrain areas. It would have then been 
possible to see if anti-emetic drug treatments could prevent the behavioural and c-fos 
changes induced by emetic treatments that may lead to a new model to evaluate anti-
emetic treatments. It was thought that studying the forebrain may have relevance to 
mechanisms that may be involved in nausea and this would represent a significant 
advance. It was only possible, however, to examine c-fos expression during these 
studies following experiments with cisplatin (due to financial constraints). 
There is some evidence suggesting that the forebrain, apart from the brainstem areas, 
is involved in the emetic reflex (see section 1.2.5.6)。In the current study, the 
technique of c-fos immunohistochemistry was applied. Although the c-fos 
immunohistochemistry has been widely used, the experimental conditions between 
different publications vary. Due to the fact that c-fos expression has been 
demonstrated in the brainstem areas (e.g. area postrema and nucleus tractus solitarius) 
after emetic stimuli (e.g. cisplatin and loperamide) (Reynolds et al., 1991; Zaman et 
al,, 2000), it was decided to work out the optimal experimental conditions by first 
_ studying the ferret brainstems after cisplatin administration, before progressing to the 
forebrain study. 
— A s mentioned in previous section, c-fos is an immediate early gene that can be 
rapidly and transiently activated upon different types of stimuli. It is suggested that a 
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peak increase in c-fos m R N A occurs approximately around 30-45 minutes after 
stimulation (Muller et al, 1984), while the o-fos gene product, Fos, has a peak 
increase detectable approximately around 1-2 hours after stimulation. (Curran et al,, 
1984; Muller et al., 1984; Sonnenberg et al., 1989). This time course profile is 
important when c-fos is being investigated using the immunohistochemical 
technique. Unfortunately, however, no Fos positive staining was observed in the 
ferret brainstems that were processed in the current studies, even though a number of 
different antibodies had been investigated. The exact reason for this failure still 
remains unknown. Moreover, since c-fos positive cells were not detected in the 
brainstem, it was decided not to investigate c-fos expression in the forebrain. 
Another original aim of the present studies was to understand the role of tacljykinin 
NKi receptors in the emetic reflex and to determine if blocking these receptors could 
prevent the potential emetogen-induced changes in c-fos expression in the forebrain. 
Tachykinins are a family of peptides that share the common amino acid sequence, 
Phe-X-Gly-Leu-Met-NK2, at their carboxyl terminal. Predominantly, there are three 
types of tachykinin receptors, namely NKi, NK2 and NK3 receptors. The preferred 
endogenous ligands for the NKi, NK2 and NK3 receptors are substance P, neurokinin 
A and neurokinin B, respectively (Regoli et al, 1994). Substance P like-
immunoreactivity has been demonstrated in various important sites along the emetic 
reflex, including the area postrema (Armstrong et al, 1981), the nucleus tractus 
solitarius (Armstrong et al., 1981; Maley, 1985) and the gastrointestinal tract (Heitz 
et al., 1976), in a number of animal species (i.e. rat, dog, cat, guinea pig, ferret and 
human). The presence of the tachykinin NKi receptors in the nucleus tractus 
solitarius, the dorsal motor vagal nuclei and the area postrema in various species (i.e. 
rat and ferret) is well known (Ariumi et al., 2000; Watson et al., 1995). Further, 
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there is evidence showing that substance P, as administered topically into the fourth 
ventricle of the urethane anaesthetized ferrets (Wood, 1988), or focally injected into 
the nucleus tractus solitarius of conscious ferrets (Gardner et al., 1996), can actually 
induce emesis. 
The tachykinin NKi receptor antagonists have a broad inhibitory profile against 
different emetic stimuli (see Table 4.1). Further, there is an increasing number of 
clinical trials that have investigated the efficacies of the tachykinin NKi receptor 
antagonists in alleviating nausea and emesis in man. The NKi receptor antagonists 
(e.g. L-754,030; CJ-11,974; L-758,298) do exhibit promising effects in alleviating 
chemotherapy-induced delayed emesis (24-72 h), as well as in attenuating 
chemotherapy-induced nausea. However, it is noteworthy that the anti-emetic 
efficacies of the NKi receptor antagonists are mainly reported in combination with 
the traditional regimes (i.e. 5-HT3 receptor antagonists plus dexamethasone) 
(Cocquyt et al, 2001; Hesketh et al,, 1999; Navari et al., 1999). Apart from the 
promising effects against the chemotherapy-induced nausea and vomiting, the 
effectiveness against the nausea and vomiting induced by the anaesthetics used in 
surgery has also been reported (Diemunsch et al., 1999). However, NKi receptor 
antagonists (i.e. L-758,298 and G R 205171) fail to alleviate motion-induced nausea 
and this may imply the anti-emetic action of the NKi receptor antagonists is not 
universal (Reid et al., 2000; Reid et al., 1998). 
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Table 4.1 Studies demonstrating the broad range of emetic stimuli against which 
tachykinin NKi receptor antagonists are effective. 
Emetic stimuli NKi receptor Species References 
antagonist studied 
Apomorphine CP-99,994 Ferret Watson et al.. 1995 
Dog Watson a/., 1995 
GR 205171 Dog Fukuda et al., 1999 
Morphine CP-99,994 Ferret Bountra et al., 1993; Saito et al., 1998 
GR 203040 Ferret Gardner et al., 1995 
Loperamide CP-99,994 Ferret Watson et al” 1995; Zaman et al.,2000 
CP-122,721 Ferret Gonsalves et aL, 1996 
Ipecacuanha CP-99,994 Ferret Bountra a/., 1993 
R113601 Cat Megens et al, 2002 
GR 203040 Dog Gardner et al., 1995 
Copper sulphate CP-99,994 Ferret Bountra et al., 1993; Saito et al., 1998; 
Watson et al., 1995 
Suncus murinus Rudd et al, 1999b; Tatter sail et a/., 1995 
CP-122,721 Ferret Gonsalves et al, 1996 
Suncus murinus Rudd et al., 1999b 
GR 205171 Ferret Gardner et al, 1996 
GR 203040 Ferret Gardner et al., 1995 
Nicotine CP-99,994 Suncus murinus Rudd etal., 1999b 
CP-122,721 Suncus murinus Rudd et al., 1999b 
RP 67580 Suncus murinus Rudd et al., 1999b 
FK 888 Suncus murinus Rudd et al., 1999b 
GR 82334 Suncus murinus Rudd et al., 1999b 
Cisplatin CP-99,994 Ferret Bountra et al, 1993; Rudd et al, 1996b 
CP-122,721 Dog Gonsalves et al., 1996 
GR 203040 Ferret Gardner et al., 1995 
Suncus murinus Gardner et al., 1995 
GR 205171 Ferret Gardner et al., 1996 
Piglet Grelot et al., 1998 
Pigeon Tanihata et al., 2003 
CJ-11,974 Ferret Tsuchiya et al., 2002 
L-741,671 Ferret Tattersall etal, 1996 
L-743,310 Ferret Tattersall etal, 1996 
Motion CP-99,994 Cat Lucoi etal., 1997 
Suncus murinus Rudd et al, 1999b 
RP 67580 Suncus murinus Rudd etal, 1999b 
GR 203040 Suncus murinus Gardner et al., 1995 
GR 205171 Suncus murinus Gardner et al., 1996 
Radiation CP-99,994 Ferret Bountra er ^z/., 1993 
GR 205171 Ferret Gardner et al., 1996 
GR 203040 Ferret Gardner et al., 1995 
Resiniferatoxin CP-99,994 Suncus murinus Andrews et al., 2000 
U46619 CP-99,994 Suncus murinus Kan et al., 2003 
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In the present studies, attempts were made to further characterize the anti-emetic 
action of the NKi receptor antagonist, CP-99,994, with a comparison of its effect to 
potentially modify behavioural activities of the ferret and Suncus murinus. 
Fortunately, the pharmacological profiles of the NK! receptor between the ferret and 
human is similar (Rupniak et aL, 1997). This facilitates the evaluation of the anti-
emetic action of the N K ] receptor antagonist in human, based upon the pre-clinical 
data obtained in ferret. Indeed, the ferret has been the most widely used animal 
model in emesis research since the development of the 5-HT3 receptor antagonists 
(Rudd et al., 1996a; Rudd et al., 1997). Whilst the ferret tachykinin NKi receptor is 
believed to be "human-like", the same receptor system in Suncus murinus is rather 
unique, being neither "human-like" nor "rodent-like" (Rudd et al., 1999b). 
In the current studies, cisplatin (10 mg/kg) and apomorphine (0.25 mg/kg) were both 
active to induce emesis in ferrets. Apomorphine had a rapid action to induce 
retching and vomiting (<5 min), but cisplatin's action was delayed (about 100 min). 
This was expected and may relate to their different mechanisms of action. Thus, 
apomorphine-induced vomiting involves a direct activation of dopamine receptors in 
the area postrema (Knox et al” 1993), but cisplatin is first metabolized to the putative 
active agent, cis-diaqodiammineplatinum (II) (DAP) and this may cause a release of 
5-HT from enterochromaffm cells to activate the emetic reflex (Matsuki et al., 1992). 
In the present studies, CP-99,994 predictably antagonized cisplatin- (Rudd et al, 
1996b; Watson et aL, 1995) and apomorphine- (Tattersall et al., 1994; Watson et al.’ 
1995) induced emesis in ferrets. It was also demonstrated that ondansetron was 
active in abolishing cisplatin-induced emesis and domperidone antagonized the 
apomorphine-induced emesis. These results with ondansetron and domperidone 
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confirm previous observations in the ferret and dog (Lefebvre et al” 1981; Rudd et 
al., 1996a; Rudd et al, 1997). 
Reynolds et al (1991) reported that the cisplatin (10 mg/kg, i.p.) induced 97.8士63.7 
retches and 13.5±11.6 vomits in ferrets following a latency of approximately 
82.5士20.6 min and caused an elevation in c-fos expression in the brainstem 
(Pveynolds et al., 1991). In the present studies，cisplatin, at the same dose and using 
the same route of administration only elicited 39.8±17.1 retches and/or vomits 
(Latency 99.3±4.8 min) in the ferrets. It should be considered that in the present 
studies cisplatin might not have achieved a threshold action to elevate c-fos 
expression. Further, a delay of approximately 15 min in the expected latency to the 
first retch and/or vomit was observed in the present studies that may also contribute 
to the failure to increase c-fos levels. Unfortunately, the exact reason for the 
discrepancies is unclear and may even be a result of using different strains of ferrets. 
Nevertheless, it is clear that a time-course experiment should have been performed to 
provide information about the correlation of c-fos expression in the brain with the 
emetic stimulus. However, due to limited time and resources, the correlation was not 
performed in the present studies, or by other workers looking at c-fos expression 
during emesis. 
Perhaps another major difficulty of the present studies was to select the optimum 
antibodies and that several antibodies have been used to probe Fos protein in the 
previous publications using ferrets (see Table 4.2). 
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Table 4.2 Summary of the primary antibodies used in different o-fos expression 
studies in ferrets. 
Stimulus on c-fos expression Primary antibody used References 
Loperamide (0.5 mg/kg, s.c.) Sheep c-fos antibody (OA 11-824) Zaman et aL, 2000 
Cambridge Research Biochemicals, U.K. 
Pulpal heat stimulation Sheep polyclonal antibody (Genosys OA Chattipakom et al., 
11-824) 1999 ‘ 
Electrical stimulation of Sheep Fos antibody, Cambridge Research Boissonade et al., 1996 
supradiaphragmatic vagal Biochemicals ‘ 
communicating branch & 
intraduodenal injection of 
hypertonic saline 
Intraduodenal injection of Sheep Fos antibody, Cambridge Research Boissonade et al., 1994 
hypertonic saline Biochemicals ， 
Tooth pulp stimulation Sheep antibody against Fos (Genosys, Oakden et al, 1998 
Cambridge, U.K.) 
Mating Rabbit Fos antiserum against the N- Lambert et al, 1992 
terminal sequence of rat FOS amino acids -
2-17 (Gift). ’ 
Proestrous surge of luteinizing Sheep anti-c-Fos (amino acid 1-14) Lee et al., 1990 
hormone antibody, (OA-11-821), Cambridge 
Research 
Cisplatin (10 mg/kg, i.p.) Primary antiserum raised in rabbit against Reynolds et a/., 1991 
a beta-gal-Fos fusion protein, Medac,  
Hamburg  
Note that, during the period of the present studies, the Sheep c-fos antibody (OA-11-824), Cambridge 
Research Biochemicals, U.K., was produced under the Sigma-Aldrich, Australia. 
In the current studies, a number of primary antibodies were used to probe the Fos 
protein in the ferret brain. The sheep polyclonal antibody to Fos oncoprotein (OA-
11-824A) from Sigma-Aldrich (Australia) was the first antibody to be tested since it 
has been most frequently used in previous publications (see Table 4.2). 
Unfortunately, the company unexpectedly discontinued the production of this 
aforementioned antibody, after two lots of supply. This was highly inconvenient and 
impaired the progress of the o-fos expression study since alternative antibodies had to 
be found and tested. Moreover, some important brain sections were also wasted. 
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Subsequently, six alternative antibodies to the Fos oncoprotein were investigated (see 
section 2.4.7). However, none of the antibodies was capable of detecting c-fos in the 
ferret tissues. Due to the inabilities in probing Fos positive cells in the ferret brain 
samples, their reactivities were then tested against commercially available Fos 
positive control (human colon carcinoma) slides (Oncogene Research Products, 
U.S.A.). 
Unexpectedly, Fos positive cells were only identified in 4, out of 6 control sections. 
It was apparent, therefore, that there is an unpredictable variation in the viabilities of 
the commercially available antibodies. It is therefore possible that the variability 
could also account for or contribute to the failure of the antibodies to identify c-fos 
i" positive cells in the ferret tissues used in the present studies. 
！ 
The primary studies were designed to correlate behavioural changes with o-fos 
expression in the ferret (see above). Clearly, the o-fos immunohistochemical aspect 
of the project failed. Therefore, the behavioural studies stand alone and still can be 
considered to be valuable. The behavioural studies were expanded from the initial 
plan to only study the action of cisplatin, once it was determined that there was a 
problem with the antibodies and the immunohistochemical technique. It was decided 
to investigate if different emetogens, with different mechanisms of action, induce a 
common pattern of activity that may be interpreted as nausea (c.f. all emetogens 
induce the behaviours of retching + vomiting). 
There are already a number of investigations attempting to study the animal 
behaviour associated with emesis. In this regard, Bermudez et al, (1988) 
demonstrated that an increase in the incidence of backward walking and burrowing 
are observed in ferret after cisplatin administration, but not lip licking and 
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defecation. More interestingly, the backward walking and burrowing behaviour were 
prevented by the 5-HT3 receptor antagonist, granisetron (Bermudez et al., 1988). In 
another study using piglet, increased chewing-like behaviour was reported after 
cisplatin administration and this was prevented by the N K ! receptor antagonist, G R 
205171. (Grelot et aL, 1998). In addition to the drug-induced associated behaviours, 
it has been reported that increased burrowing and lip licking are also observed after 
radiation treatment (King et al” 1990). In a more recent study concerning with 
loperamide, elevated frequencies of lip licking, mouth scratching, wet dog shake and 
gagging are also observed (Zaman et al, 2000). It is perhaps important that the 
loperamide-induced associated behaviours are prevented by the NKi receptor 
antagonist, CP-99,994 (Zaman et al., 2000). It is clear that different behavioural 
repertoires may result from treatment with different emetic stimuli and these findings 
must be examined to test the hypothesis that the behaviours can be regarded as 
measures of nausea. However, this casual link is still far from perfect since some 
negative findings have also been obtained in other studies. For example, Gonsalves 
and co-workers (1996) found that gagging, lip licking and backward walking 
behaviours induced by copper sulphate and loperamide in ferret were not 
antagonized by the NKi receptor antagonist, CP-122,721, although the same dose of 
drug antagonized the retching and vomiting. Because of this, the authors questioned 
the direct relationship between these associated behaviours and the sensation of 
nausea (Gonsalves et al., 1996). 
In contrast to the different types of behaviours mentioned above, there are fewer 
studies reporting the locomotor activity of animals after administration of emetic 
stimuli. In 1990，King et al. attempted to study the locomotor behaviour (as 
measured by photocell beams) in ferrets after radiation. In the study, radiation was 
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found to decrease locomotor activity of the animals and the reduction of activity was 
prevented by the 5-HT3 receptor antagonist, batanopride ( B M Y 25801). 
Notwithstanding this intriguing finding, it was also noteworthy that zacopride 
(another anti-emetic investigated in the same study), also suppressed locomotor 
activity as administered alone (King et al, 1990). Indeed, this is a good example to 
highlight the possibility that an anti-emetic itself may actually affect locomotor 
behaviour directly，rather than acting to reduce nausea. Therefore, an interpretation 
of any locomotor data should be carefully made. 
In the ferret, it was decided to compare the profile of activity of the cisplatin-treated 
animals with the behaviour of the ferrets treated with apomorphine. The emetic 
mechanism of the initiat action of cisplatin (10 mg/kg) to induce emesis 
predominantly involves the peripheral vagus nerves, 5-HT and 5-HT3 receptors 
(Andrews et al, 1988b). The emetic mechanism of action of apomorphine involves 
the area postrema and dopamine D2 receptors (Knox et al., 1993). In the present 
studies, the animal behaviour was compared by examining the spontaneous 
locomotor activity (the distance travelled and the velocity of movement) and a 
number of behavioural responses (e.g. lip licking, curling up, burrowing, backward 
walking, rearing and defecation). 
In the current studies, the spontaneous locomotor activity data and the velocity data 
of animals were analyzed in two different ways, with or without data normalization 
(either with respect to the data in the Habituation period or the Pretreatment period). 
In fact, data normalization was regarded to be necessary as some of the animals did 
have different levels of basal activity (in the Habituation period) even if the Latin 
Square randomization protocol had been strictly followed. However, the two 
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different normalization methods adopted occasionally generated different 
conclusions in the same experiment (see below). 
In the present studies, analysis of raw data revealed different effects in animal 
spontaneous locomotor activity that were induced by cisplatin (10 mg/kg) and 
apomorphine (0.25 mg/kg). Whilst cisplatin induced no change in the two locomotor 
measures, apomorphine (0.25 mg/kg, s.c.) increased the distance travelled and 
velocity of movement in the experiment involving domperidone, but not with CP-
99,994. However, different trends could be seen in the normalized data. Whilst 
cisplatin consistently had no effect to alter the spontaneous locomotor activity in the 
normalized data, but apomorphine tended to induce an increase in the same 
measures, even in the experiment involving with CP-99,994. The elevation in 
locomotor activity is not unexpected as apomorphine (0.2 mg/kg, s.c.) also increases 
locomotor activity in pigs (Terlouw et al, 1992). Besides, both of these emetogens 
failed to affect any of the associated behaviours in the animals. These findings 
confirm previous observations that different emetogens might actually induce 
different patterns of behaviours。 
Apart from studying the effect of two emetogens, attempts were also made on the 
effect of the potential antagonists (i.e. ondansetron, domperidone and CP-99,994) 
against the animal behaviours。In the normalized data, ondansetron, alone or in 
combination with cisplatin, failed to affect the spontaneous locomotor activity, 
except with a minor alteration in defecation frequency. This finding was also not 
unexpected as ondansetron does not alter locomotor activity (as measured by infra-
red photo beams) in social interaction test in rat (Jones et ah, 1988), although it has 
been reported to induce modest sedation in man (Hesketh et al, 1989; King, 1990). 
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In the same experiment, analysis of raw data revealed that CP-99,994, as a single 
treatment, seemed to reduce the spontaneous locomotor activity of the ferrets. 
However, CP-99,994, alone or in combination with cisplatin, seemed to be active to 
increase spontaneous locomotor activity of the ferrets, when the normalized data was 
inspected. This ability to activate animal behaviour was also demonstrated by its 
action to decrease the curl up frequency in another experiment with apomorphine. 
Unfortunately, this observation was not consistent compared to the experiment with 
cisplatin and it is therefore difficult to make a firm conclusion. Nevertheless, apart 
from the effects on the above behaviours, CP-99,994 also seemed to reduce 
spontaneous lip licking in the ferrets. Whilst it has been reported that CP-99,994 is 
able to reduce or abolish the lip licking behaviour induced by different emetic stimuli 
(e.g. loperamide (Zaman et al, 2000); electrical stimulation (Davidson & Pilot， 
1993; Watson et al., 1995)), none of the previous studies investigated the 
spontaneous lip licking behaviour during the Habituation period and therefore CP-
99,994 was considered to have a potential to reduce nausea. Nevertheless, consistent 
with the previous studies, CP-99,994, in combination with emetogens (cisplatin or 
apomorphine in the present studies) reduced the number of lip licking behaviour 
when compared to the instances where the emetogens were administered alone. 
Although, the lip licking behaviour has been interpreted as being representative of 
nausea (Grelot et al., 1998), it is possible that the effect of NK] receptor blockade on 
lip licking behaviour may also involve an alteration in the taste perception or is a 
secondary action to reduce salivation (Ciccocioppo et oL, 1994; Furukawa et al, 
1998). Domperidone was clearly anti-emetic in the present studies to reduce 
apomorphine-induced emesis and also displayed a trend to reduce the apomorphine-
induced increases of spontaneous locomotor activity (as seen from an analysis of the 
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normalized data). The finding to almost reduce locomotor activity was unexpected 
since domperidone does not easily access the CNS; the action to reduce emesis was 
predicted from its ability to block dopamine D2 receptors that are easily accessible in 
the area postrema (Leslie & Reynolds, 1993). 
In addition to the studies in ferrets, the profile of behaviour of Suncus murinus 
following treatment with emetic drugs was also investigated in the present studies. 
These studies were more detailed that it was possible to study the action of emetic 
drugs at sub-emetic doses (i.e. just below doses inducing emesis). It was thought that 
this would be more relevant to behaviours involved in nausea. Yet, in contrast to the 
ferret studies where a number of general animal behaviours (e.g. lip licking, 
t" burrowing, backward walking etc.) were expressed, the Suncus murinus would 
f 
‘ generally only become stationary prior to vomiting. Therefore, it was only possible 
to investigate the actions of the emetic stimuli on spontaneous locomotor activity and 
the velocity of animal movement. 
In the present studies, nicotine induced a dose-dependent decrease in the spontaneous 
locomotor activity and velocity of movement of Suncus murinus. However, 
significant differences were only observed at the emetic dose of 5 mg/kg, s.c. In 
contrast, both copper sulphate and cisplatin failed to induce changes in the two 
measures. Although it may be plausible that different emetic stimuli might exert 
different behavioural profiles in the animals, it is also possible that the decrease in 
locomotor activity observed following nicotine treatment was actually due to the 
neuromuscular blockade (caused by -the persistent activation of the nicotinic 
receptors in the neuromuscular junction) (Rang et al” 1999a). Surprisingly, 
however, the effect of nicotine to reduce locomotor activity was not seen in a second 
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experiment involving the use of CP-99,994. However, in the first experiment, the 
basal activity of the animals was considerably higher than in the experiments using 
CP-99,994 and it may therefore be easier to detect a decrease in locomotor activity. 
In any event, CP-99,994 had no effect on locomotor activity, alone or in combination 
with nicotine or copper sulphate. 
Originally, it was decided to compare the different effects exerted by CP-99,994 and 
ondansetron against the cisplatin-induced behavioural actions. However, it was 
found that the casual comparison between the two treatments was far from perfect as 
the locomotor activity measured from the vehicle-treated animals was varied 
between the two groups of animals. Unfortunately, it is not possible to exclude the 
fact that the variations may be a consequence of different nature of vehicles used, as 
well as the difference in the routes of administration, in addition to the variations in 
the behaviours of the animals。Moreover, the differences were still unexpected since 
a Latin Square had been strictly followed. In fact, variation in animal behaviour was 
presented as a problem in the current studies. 
It‘ should be noted that CP-99,994 (3-10 mg/kg, i.p. or s.c.) dose-dependently 
decreased nicotine (5 mg/kg, s.c.)- and copper sulphate (120 mg/kg, intragastric)-
induced emesis。The inhibitory action of CP-99,994 was similar to the findings that 
have been previously published (Rudd et al., 1999b). However, the anti-emetic 
efficacy of CP-99,994 (3-10 mg/kg’ s.c.) against cisplatin (30 mg/kg, i.p.)-induced 
emesis in Suncus murinus has not been reported previously. Although a dose-
dependent decrease in the number of vomiting episodes was observed, the 
magnitudes of inhibition among the three emetic stimuli used were of different 
extents. Thus, the rank order of potency of CP-99,994 to reduce the number of 
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vomiting episodes were as follows: Copper sulphate (120 mg/kg) > nicotine (5 
mg/kg) > cisplatin (30 mg/kg)。More importantly, it was found that none of the test 
animals in the present studies were totally protected from emesis, even at the higher 
dose (i.e. 10 mg/kg) of CP-99,994. This finding is in contrast to the effect of 
ondansetron that increasing numbers of animals were totally protected from emesis 
when the dose was increased. Further, these observations are also in contrast to the 
findings in ferrets (see above) where CP-99,994 was active to abolish emesis induced 
by both cisplatin and apomorphine. Actually, the discrepancy may be explained by 
the difference in receptor affinity of CP-99,994 between the two species. Whilst the 
IC50 value of CP-99,994 to displace Hunter-substance P in the ferret 
tachykinin NKi receptor is reported to be 1.97nM (Watson et al., 1995), the value in 
Suncus murinus is 12nM (Tattersall er al., 1995). Obviously, this further supports 
the proposition that the NKi receptor system in Suncus murinus is actually unique in 
nature, which is neither "human-like" nor "rodent-like" (Rudd et al” 1999b). 
Consistent with the observations in ferrets, ondansetron, administered alone, failed to 
modify the spontaneous locomotor activity in Suncus murinus. However, a species 
difference was observed with regard to the action of CP-99,994. Whilst CP-99,994 
seemed to activate behaviours in ferrets, it imposed no effect in Suncus murinus as 
administered alone. Nevertheless, this finding is not surprising as it has been 
demonstrated that subcutaneous administration of CP-99,994 failed to modify 
spontaneous locomotor activity in the guinea pig (as measured electronically by 
crossovers from one quadrant of the cage floor to another) after habituating to a 
novel environment (McLean et al., 1993). 
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As mentioned earlier, spontaneous locomotor activity and general behaviours of 
animals were analyzed by two main ways in the present studies: with or without data 
normalization. For simplicity, it is always advantageous if the raw data of animal 
activities can be compared directly. However, this was difficult as there were 
variations in basal activity among some animals. In this regard, these discrepancies 
can actually be eliminated by data normalization. However, this type of data analysis 
is not applicable to all of the data, such as the general behavioural measures in the 
ferrets, in which zero score might be recorded. In the present studies, the 
spontaneous locomotor measures of animals in the Test periods had been normalized 
to the Habituation data, as well as the Pretreatment data. It is difficult to justify the 
superiority of either one of these normalization methods. However, there is a rule of 
thumb that, if the pretreatment of any potential antagonists failed to alter with the 
spontaneous locomotor measures in the Pretreatment period, the Test data can just be 
normalized to the Pretreatment data and compared. In fact, this is the case in the 
present studies and that the Test data normalized to the Pretreatment data may be a 
more appropriate method for analysis. This is advantageous as the effect of 
emetogens, before and after its administration, can be directly compared. 
By virtue of the fact that the NKi receptor antagonists can inhibit emesis induced by 
a wide variety of stimuli (see Table 4.1), the anti-emetic action must be at a 
convergence point of different afferent inputs, or is close to the outputs of the 
vomiting centre (Rupniak et al., 1999). In this regard, the nucleus tractus solitarius 
has been suggested to be a candidate site (Watson et al., 1995). This is based on its 
anatomical characteristics and its reciprocal connections with the area postrema 
- (Leslie & Reynolds, 1993; Miller et aL, 1994), and it also receives information from 
the vagus (Leslie & Reynolds, 1993) and vestibular system (Yates et al., 1994). 
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Apart from the nucleus tractus solitarius, the possibility of the area postrema as the 
site is less plausible since area postrema ablation is ineffective to affect the anti-
emetic action of CP-99,994 in preventing copper sulphate-induced emesis in the dog 
(Andrews et al., 2001). A central site of action of the NKi receptor antagonists is 
further suggested based on a number of studies showing that the anti-emetic 
efficacies of the drugs are dependent on their brain penetrating ability (Rudd et aL, 
1999b; Rupniak et aL, 1997; Tattersall et al., 1996). 
Although it is believed that the site of action of the N K ] receptor antagonists is 
"deeper" in the vomiting reflex when compared to classical anti-emetics and maybe 
in a pivotal point along the emetic reflex, the NKi receptors seem not to be the final 
receptor system involved as it is clear that the N K ! recei|tor antagonists are not active 
towards all emetic stimuli. For example, a study in the Suncus murinus highlights 
that the NKi receptor antagonist, CP-99,994, is unable to prevent the emesis induced 
by the mechanical stimulation of the upper gastrointestinal tract (Andrews et al,, 
1996). Clearly, much work is required to understand the receptor systems involved 
in emesis control and it would be ideal if the present studies could be repeated (with 
variation in some of the protocols) to search for new brain areas that may be involved 
in the control of nausea and emesis. 
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CHAPTER 5 GENERAL SUMMARY 
The studies were performed in an attempt to identify forebrain areas involved in 
emesis control and to clarify the site and mechanism of action of 'broad inhibitory' 
anti-emetic drugs. If specific forebrain areas had been identified, it would have been 
possible to plan more elaborate experiments to confirm their role in the emetic reflex. 
These would have included lesioning experiments and local pharmacological 
modulation of the transmitter systems present in the identified forebrain areas using 
intracerebral injections. The studies could have provided valuable information that 
may have lead to the development of animal models that could be used to identify if 
new prototype anti-emetic drugs have the potential to prevent "emetic information" 
from reaching the forebrain from the brainstem - this may have had relevance to 
nausea control mechanisms. 
It was planned to use the technique of c-fos immunohistochemistry to identify the 
brain areas involved in the emetic reflex. This is because the technique has been 
used successfully by other investigators to map brainstem site involved in emesis 
control. Cisplatin was selected for the main part of the studies since the"mechanism 
of emetic action has also been studied extensively in animals and man. 
Unfortunately, however, there was a problem in obtaining some of the commercially 
available antibodies during the project that was not predicted at the start of the 
studies. Consequently, much valuable time (almost 1 year) was lost on the project 
trying to compensate for the interruption of antibody supply and many valuable 
tissue sections had to be discarded. There may have also been other inherent 
problems-with the <z-fos immunohistochemical technique (including variability in the 
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viability of other commercially available antibodies) and the ferret tissues that were 
not entirely resolved during the course of the studies. 
The project was also concerned with investigating if drug treatments could 
induce/inhibit behaviours that have been previously thought to be indicative of 
nausea in animals. In the ferret, this part of the study ran concurrently with the c-/os 
measurements, and as such, had to be non-invasive, since any intervention may have 
had consequences on the anticipated c-/os changes in the brain. Therefore, it was not 
possible to make biochemical measurements (e.g. of vasopressin levels) or to use the 
classic paradigms of conditioned taste aversion or pica, as they are not ideally suited 
the o f OS protocol. For these reasons, it was planned to look at general animal 
behaviour and locomotor measures that have also been used by others to assess r 
nausea and emesis. . 
The present studies can be considered to be the first to carefully study ferret and 
Suncus murinus behaviours necessary for a correct interpretation of data relevant to 
nausea and emesis. Other studies have been less rigorous in that they have not 
investigated thoroughly the spontaneous activity of animals prior to experimental 
handling. In particular, the present studies clearly demonstrated that certain 
behaviours that have been taken as indicative of nausea，for example lip licking, 
backward walking and burrowing, actually occur in normal healthy animals. Indeed, 
the studies were not able to demonstrate a behaviour that is specifically expressed 
(excepting retching and vomiting) in response to treatment with either cisplatin or 
apomorphine in the ferret, or to nicotine, copper sulphate and cisplatin, in Suncus 
murimis; the action of emetogens in Suncus murinus were examined at emetic and 
sub-emetic doses. It is not known, therefore, how lip licking, backward walking or 
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burrowing can represent 'nausea behaviours', unless the animals continuously 
express a low level of nausea and this seems highly unlikely. 
In some previous studies, the ability of N K ! receptor antagonists to reduce emetogen-
induced lip licking has been suggested to reflect a capacity to reduce nausea in 
animals. However, the present studies have shown that CP-99,994 alone can reduce 
spontaneous lip licking episodes and this would clearly invalidate any assumption 
made about the ability of CP-99,994 to reduce nausea. Again, the previous studies 
did not carefully study the effect of drugs on spontaneous behaviours. The present 
studies suggest that the effects on lip licking by NKi receptor antagonists have been 
misinterpreted. The changes in this behaviour may simply reflect an alteration in 
taste sensitii^ ity or changes in salivary function that may occur independently from 
mechanisms controlling nausea and emesis. Similarly, CP-99,994 in some 
experiments in the ferret had an action to increase locomotor activity (i.e. distance 
travelled and velocity of movement) when used alone and in combination with 
cisplatin and therefore cannot be simply taken as evidence that CP-99,994 can reduce 
nausea. It also reduced the curling up frequency in an experiment involving 
apomorphine that further suggests that CP-99,994 stimulates locomotor activity. 
The studies encompassed a detailed investigation of the effect of emetic drugs on 
spontaneous locomotor activity in ferret and Suncus murinus. However, this aspect 
of the present studies was complicated by variation of the spontaneous locomotor 
activity expressed by individual animals that was not easy to balance, even when 
using a strict randomization protocol. Nevertheless, cisplatin had no effect to modify 
locomotor activity in the ferret but apomorphine appeared to increase the distance 
travelled and the velocity of movement. However, in Suncus murinus, cisplatin in 
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one experiment appeared to reduce locomotor activity, as did nicotine, but copper 
sulphate had no action to modify behaviour (all three drug treatments induced a 
comparable level of emesis). Clearly, emetic drugs do not have a consistent action to 
modify locomotor activity and any such changes in activity should not be simply 
viewed as a consequence of mechanisms operating in relation to the emetic reflex. 
This is because the emetic and anti-emetic drugs themselves may have other 
pharmacological prosperities that may affect behaviour either by acting at central or 
peripheral sites that are independent from the emetic circuits. Certainly, it was 
apparent that doses of ondansetron and domperidone that could antagonize emesis 
and that are known to reduce nausea in man had no effect on the emetogen-induced 
changes in locomotor activity further suggesting that locomotor activity changes 
observed in the present studies are not ideally indicative of an index of nausea. 
In conclusion, emetic drugs have a common potential to induce retching and 
vomiting and this behavioural change is easy to quantify. In contrast, emetic drugs 
may induce different patterns of other behaviours that are difficult to interpret as 
being indicative of nausea: there are also species differences between the action of 
emetic drugs in the ferret and Suncus murinus. It was disappointing that the c-fos 
investigations were disrupted since this may have revealed much information about 
forebrain areas that may be involved in nausea and emesis and would have 
complemented the behavioural data that now stands alone. Nevertheless, the present 
studies confirm and extend the broad inhibitory potential of the NK! receptor 
antagonists to reduce emesis and the anti-emetic action of ondansetron and 
domperidone. The studies also provide a valuable framework for future studies on 
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